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Abstract	
Staphylococcus epidermidis is a substantial element of the healthy human skin microflora and can 
become pathogenic to cause infections, for example, septicaemia and endocarditis. The effects of 
long-term sub-lethal exposure to antibiotics on the skin microbiota are unknown. How does antibiotic 
adaptation affect the ability of S. epidermidis to interact with host immune systems, inhibit pathogens 
and keep a healthy microflora? This project aims to characterise five S. epidermidis bacteria samples 
isolated from the skin, before and after exposure to antibiotics thus comparing their antibiotic 
susceptibility pattern (disc diffusion assay), biofilm formation (crystal violet microtitre plate assay) and 
microbial virulence (G. mellonella infection assay). Serially passaged antibiotic-adapted strains were 
also assessed for the following characteristics: colony and cell morphology, cross-resistance (to other 
antibiotics), growth rate and competitive fitness ability. S. epidermidis parent strains were firstly 
susceptible to antibiotics such as erythromycin and doxycycline, and later formed adaptive resistance. 
Erythromycin adapted strains were found to be resistant to erythromycin and cross- resistant to 
doxycycline based on both disk diffusion assay and MIC results. Doxycycline adapted strains formed 
resistance to doxycycline based on both disk diffusion assay and MIC results. Significant differences (p 
<0.05) were observed in the mean relative biofilm units and G. mellonella infection assay survival rates 
of antibiotic-adapted strains of S. epidermidis. Erythromycin adapted strain had significantly enhanced 
fitness advantage (w value- 1.35, p value- 0.0427) and were significantly virulent (p-value of 0.0065) 
when compared to the parent strain. Doxycycline adapted strain showed significantly lower fitness 
advantage (w value- 0.38, p-value 0.0005) yet, they were significantly virulent (p-value of 0.0059) in 
comparison to the parent strain. These findings highlight the implications of adaptive resistance to 
antibiotics in the treatment of S. epidermidis infections, and therefore necessitate the development 
of more sophisticated future treatments for bacterial infections. It is important for the private and 
public healthcare sectors worldwide to invest in the advancement of new anti-infectives to combat 
the growing antibiotic resistance.
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Chapter	1	
1.0 Introduction		
1.1	Skin	microbiome	and	Staphylococcus	epidermidis		  
The human skin microflora has a vital role to play in health and disease. The growing arsenal of 
experimental methods are rapidly reaching new horizons in the research of human to microbe and 
microbe to microbe interactions. The skin covers around two square metres of the human body while 
maintaining the body integrity, it is the biggest organ in regard to surface area. The skin allows the 
body to interact with its surroundings and provide protection from several physical, mechanical, 
biological and chemical assaults (Leonel et al. 2019). In addition to this, the skin allows the human 
body to remain “healthy” by inhibiting external pathogenic microbes from entering and preventing 
the body from losing critical internal fluids. The skin also keeps individuals healthy by transmitting 
sensations and balancing body temperature (Leonel et al. 2019). The skin constantly regenerate cells, 
hence, it is a self-renewing organ. The skin involves an outer layer, epidermidis, a subjacent connective 
tissue, dermis, and subcutaneous tissue (Grice & Segre, 2011). Every skin site is composed of several 
components, including melanocytes, keratinocytes and Langerhans cells in the epidermis, fibroblasts, 
pericytes, immune cells, nerve endings and endothelial cells in the dermis, and adipocytes in the 
subcutaneous tissue (Grice & Segre, 2011).  
An ecogenomic study discovered that Staphylococcus and Corynebacterium species are the prevailing 
microbes colonising moist skin sites, culture data also suggests that these micro-organisms favour high 
humidity skin sites (Grice & Segre, 2011) (Figure 1). These high humidity areas involve the axillary 
vault, umbilicus (navel), the gluteal crease (topmost part of the fold between the buttocks), the 
inguinal crease (side of the groin), the popliteal fossa (behind the knee), the antecubital fossa (inner 
elbow) and the sole of the foot (Figure 1). Staphylococci inhabit aerobic sites on the skin and may 
utilise the urea present in sweat for nitrogen. Processing of apocrine sweat by Staphylococci (and 
other axillary vault microbes) causes the malodour characteristic connected to humans sweat (Figure 
1) (Grice & Segre, 2011). One of the major Staphylococci species identified on human skin is 
Staphylococcus epidermidis, commonly inhabiting nares, axillae and the head (Dreno et al., 2016). 
Staphylococcus epidermidis is the most dominant Gram-positive, coagulase-negative cocci commensal 
on the healthy human skin microflora. S. epidermidis is responsible for about 60-70% of all coagulase-
negative Staphylococcal species on the stratum corneum (Dreno et al., 2016). 
Non-bacteria microbes have also been identified from the skin (Figure 2A). Malassezia species are the 
most frequently isolated fungal species, found mainly in sebaceous areas. The Demodex mites 
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including Demodex folliculorum and Demodex brevis are microscopic arthropods and are a part of the 
normal skin microflora (Figure 2A) (Grice & Segre, 2011). Sebum provide Domodex mites nourishment, 
hence, mites are abundantly found after puberty, choosing to colonise sebaceous regions of the face. 
Demodex mites can similarly feed off epithelial cell lining the pilosebaceous unit and feed on 
microorganisms that inhabit the same area e.g. Propionibacterium acnes. The function of viruses as a 
skin commensal has not yet been researched, research is restricted by the current microbiological and 
molecular means to isolate and classify viruses (Figure 2A) (Grice & Segre, 2011). 
 
Figure 1. Human skin sites with bacteria Microbes that are considered as skin commensals involve: 
Coryneforms of the phylum Actinobacteria (the genera Corynebacterium, Propionibacterium and 
Brevibacterium) and the genus Micrococcus (Grice & Segre, 2011). Bacteria family classification is 
shown alongside the phyla in bold. Different skin sites: sebaceous or oily (blue circle), moist (green 
circles) and dry or flat skin (red circle). The sebaceous sites are: alar crease (edge of the nostril); 
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glabella (amongst the eyebrows); auditory canal (within the ear); occiput (behind the scalp); 
retroauricular crease (behind the ear); manubrium (top chest area); and back. Moist sites are: axillary 
vault (armpit); nare (within the nostril); antecubital fossa (inner elbow); interdigital web space (area 
between the middle and ring fingers); inguinal crease (side of the groin); gluteal crease (upper area of 
the crease between the buttocks); popliteal fossa (back of the knee); plantar heel (underneath the 
heel of the foot); toe web space; and umbilicus (navel). Dry sites are: hypothenar palm (palm of the 
hand proximal to the little finger); volar forearm (inner area of the mid-forearm); and buttock (Grice 
& Segre, 2011). 
  
Figure 2A. Skin anatomy illustration with skin commensals and appendages (Grice & Segre, 2011). 
Commensal Staphylococcus epidermidis remain in the skin epidermis where there are no blood 
vessels. If S. epidermidis reach the blood vessels in the dermis, it can spread to other areas of the body 
and cause disease. Microbes (bacteria, viruses and fungi) and mites coat skin surface area and inhabit 
deep inside the gland and hair. Rod and round bacteria e.g. Proteobacteria 
and Staphylococcus species, respectively. These microbial populations are acutely intertwined 
between themselves and other microorganisms. Fungi that exist in a state of commensalism on the 
skin e.g. Malassezia species grow both as dividing filamentous hypha and as singular cells. Elements 
of virus can exist both freely and in bacterial cells. Demodex folliculorum and Demodex brevis skin 
mites are one of the tiniest arthropods and live inside or close to hair follicles. Hair follicles, sweat 
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glands and sebaceous glands are few examples of skin appendages illustrated (Grice & Segre, 2011). 
The skin is usually cool, acidic and dry, variation of the skin microflora is reliant on the cutaneous site 
thickness, folds, density of hair follicles and glands. The outermost layer of the epidermis is the 
stratum corneum, of which 90% epidermis cells are made up of terminally differentiated keratinocytes 
(corneocytes). Squames (enucleated keratinocytes) comprises of keratin fibrils that are crosslinked. 
The keratin can retain large volumes of water between the fibers. Cornified envelopes are situated in 
the lipid bilayers, producing the ‘bricks and mortar’ of the epidermidis. Squames migrate from the 
basal layer of the skin to the outer skin surface and shed, this process could take four weeks (Grice & 
Segre, 2011). 
 
 
 
 
 
 
 
 
Figure 2B. Factors contributing to variation in the skin microbiome (Grice & Segre, 2011). Factors such 
as age, anatomical location and gender can influence the variation of microflora in skin. The skin has 
approximately 12 to 16 layers of corneocytes, and each corneocyte has an average thickness of 1 
micrometer, depending on the age, anatomical site, and UV radiation exposure (Grice & Segre, 2011). 
Male and female skin environment differ physiologically and anatomically, for example, producing 
different concentrations of sweat, sebum and hormone for different skin sites, this partly accounts for 
the bacterial variances seen between both sexes (Grice & Segre, 2011). Environment specific to an 
individual including clothing choice, occupation and drug usage, may regulate skin microflora 
colonisation. Skin care products, soaps, body/face wash products, moisturisers and cosmetics, are all 
possible factors that influence the skin microflora variations. These products can modify the skin 
barrier condition, however, how it may affect the skin microflora is unclear. Measureable skin culture 
samples highlighted that high-humidity and high-temperature correlates to increased amounts of 
commensal microbes on the axillary vaults, back, and feet compared to high-temperature and low 
humidity environment (Grice & Segre, 2011).   
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The human skin is an organ which functions as a highly complex barrier while symbiotically interacting 
with bacterial populations via adaptive and innate immune system signals. Bacteria provide important 
nutrients, affecting cellular metabolism and strengthen the immune system (Figure 3) (Grice & Segre, 
2011; Baldwin et al., 2017). Loss of protective bacteria intensifies inflammatory skin diseases (Williams 
& Gallo, 2017). The skin is always exposed to countless exogenous and endogenous elements which 
influence symbiosis, possibly leading to inflamed skin, skin allergies, infections, cutaneous tumour 
formation or autoimmune illnesses (Bukhari, 2015; Leonel et al., 2019). The gastrointestinal tract and 
faeces microflora have been researched and documented for several years while the skin or scalp 
microflora has not been investigated till recently (Bukhari, 2015). 
In a recent study, it has been reported that S. epidermidis strains obtained from healthy patients’ skin 
could induce a gathering of CD8+ T lymphocytes in the skin via dendritic cells presentation of antigens 
(Linehan et al., 2018). However, S. epidermidis strains that stimulate accumulation of CD8+ T 
Figure 3. Stimulation of innate immunity. Agents that may possibly cause dysbiosis and 
the human host innate immune response of the skin (Dreno et al., 2016). 
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lymphocytes in the skin were absent from adult humans with skin disease (Linehan et al., 2018). 
Linehan et al. (2018) analysed S. epidermidis genome and carried out in vitro experiments to find major 
histocompatibility complex Ib (MHCIb) on dendritic cells, the cells displayed N-formyl methionine 
peptides, which are secreted by S. epidermidis, to CD8+ T lymphocytes. The researchers completed 
RNA sequencing of CD8+ T lymphocytes which were induced by or linked to S. epidermidis. After 
evaluating the global transcriptome, results revealed that CD8+ T lymphocytes can up-regulate various 
genes linked with immune regulation and tissue repair (Grice & Segre, 2011; Linehan et al., 2018). In 
addition to this, Linehan and colleagues also investigated the effects of S. epidermidis on skin injury 
via punch biopsy method. Interestingly, S. epidermidis stimulated CD8+ T cells, which facilitated re-
epithelisation of the injured skin and promoted wound healing.  
One of the functions of the skin microbiota is to avoid unwanted pathogenic bacteria from colonising 
the skin, this maintains an environmental equilibrium in each skin niche. The configuration of the skin 
microflora may largely influence medical progression for treating cancer, as cancer that use 
procarcinogenic or anticarcinogenic actions mainly rely on a balanced skin microflora (Garrett, 2015; 
Nakatsuji, et al. 2018). Skin microbiota can add to carcinogenesis, by augmenting or reducing a host’s 
risk, this can be categorised into three general groups: (i) modification of the host cell proliferation to 
death ratio (ii) influencing host immune system function and (iii) manipulation of host metabolism 
(Garrett, 2015). Thus, it is vital to keep a balanced skin inhabitant populace to also preserve a healthy 
gut microbiota (Dreno et al., 2016). 
For microbes to colonise the human skin they must resist environmental factors (injury, UV exposure, 
anxiety, and hygiene) which constantly change compared to the protected areas of the body (Dreno 
et al., 2016) (Figure 1 &3). The skin microenvironment undergoes constant fluctuation in mechanical 
stress, pH value, salt concentration and osmolarity. The commensal bacteria must adapt to the dry 
and moist skin conditions. There are only few known bacteria that can withstand high salt 
concentrations or other extremities on human epithelia. Non-halophilic Staphylococci are known to 
have an extraordinarily high capacity to resist such influences, especially high levels of salt (Espadinha 
et al, 2019). S. epidermidis is unaffected by the harsh surroundings that usually occur in its natural 
habitat due to the genes it may possess. For instance, S. epidermidis can survive extreme salt and 
osmotic pressures via six transport systems for osmoprotectants and eight sodium ion / proton 
exchangers (Dreno et al., 2016). The ability to form biofilms help the bacteria to survive harsh 
conditions significantly. Over the years a large amount of osmoprotective elements have been 
expressed and reported in S. epidermidis biofilms (Mirzaei et al., 2017). Also, S. epidermidis is 
anticipated to not only have unharmful interaction with the host but have a probiotic function as well. 
This may exist to avoid more infectious bacteria colonising the skin such as Staphylococcus aureus. 
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Nevertheless, no distinct evidence has been found to verify that S. epidermidis is capable of secreting 
factors that may influence colonisation of other microbes in vivo (Mirzaei et al., 2017). Certain variants 
of S. epidermidis yield differing lantibiotics including, Pep5, 15X, epidermin and epilancins K7, these 
lantibiotics are highly toxic and deadly for several Gram-positive bacteria (Espadinha et al, 2019). 
 
Healthy skin microflora may influence the host cells leading to a stronger host defence system against 
other pathogenic microbes. S. epidermidis can induce endogenous antimicrobial peptides (AMPs) e.g. 
β defensins, hence, reinforcing the host defence system against S. aureus (Noreen et al., 2015).  S. 
epidermidis is capable of activating mast cell-induced anti-viral host defence mechanism, for it to 
control inflammatory responses throughout the wound healing process, while encouraging the 
production of stratum corneum AMPs and inducing cutaneous T-cell development (Noreen et al., 
2015). S. epidermidis hence work to protect the skin by communicating with the host immune system. 
Furthermore, the skin microbiota may symbolise as a filter for the environmental agents interacting 
with or breeching the skin. There is also evidence available on how the biological determined host 
immune system has a strong hold on the assembly of the microflora (Noreen et al., 2015). 
Alternatively, once the existence of the skin microbiome is sensed via Toll like receptors (TLRs), 
epidermal Langerhans cells can induce naïve T cells to pedestal a Th17 reaction, this allows 
keratinocytes to control the AMPs emission (Noreen et al., 2015). Consequently, other than human 
innate immune system and dendritic cells in the epidermis, TLRs also appear to instruct the adaptive 
immune response, thus encouraging the complicated regulation of the bacteria growing in the skin 
(Noreen et al., 2015). 
1.2	Commensal	S.	epidermidis	preventing	skin	cancer	
Nakatsuji et al. (2018) have recently identified certain variants of S. epidermidis that produce 6-N-
hydroxyaminopurine (6-HAP) with the capacity to block DNA polymerase activity. Intravenous 
inoculation of 6-HAP inhibited melanoma B16F10 progression from occurring in mice and there was 
no sign of toxicosis. Mice was also colonised with 6-HAP producing S. epidermidis strain, resulting in a 
low prevalence of ultraviolet-induced tumours compared to mice colonised with a non - 6-HAP 
producing S. epidermidis control strain. 6-HAP producing S. epidermidis strains were found in several 
healthy human skin microbiota indicating that the skin microflora of particular individuals may provide 
protection against skin neoplasia (Nakatsuji et al. 2018).  
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Figure 4. S. epidermidis stimulate wound recovery and tumour deterioration in the skin (Leonel et al., 
2019).  Recent studies suggest novel roles for S. epidermidis in the skin microenvironment (Linehan et 
al., 2018; Nakatsuji et al., 2018). S. epidermidis support wound healing through an assemblage of CD8+ 
T lymphocytes in the skin and inhibit cutaneous tumour development via 6-N-hydroxyaminopurine 
secretion. Future research will demonstrate detailed cellular and molecular mechanisms entailed in 
the relations between skin microbiota and numerous factors of the skin microenvironment (Grice & 
Segre, 2011; Leonel et al., 2019).  
1.3	 The	influence	of	gut	microbiome	on	skin	microbiome		
Several lines of evidence have indicated that there is a bidirectional communication between the gut 
microbiome and the skin microflora as various studies connect healthy gastrointestinal to skin 
homeostasis and allostasis (Levkovich et al., 2013). Gastrointestinal illnesses and differences in the 
gastrointestinal system usually show signs and symptoms on the skin (O’Neill et al., 2016). The gut 
microflora commonly indicate change in the pathophysiology of various inflammatory diseases (Shah 
et al., 2013; Thrash et al., 2013; Gloster et al., 2016).The gut microbiome has a great impact on the 
gastrointestinal system and can be used for healing purposes by supplementing or prescribing 
probiotics. Furthermore, the gut microbiota has been observed to have an effect on the skin 
microbiota (Schwarz et al., 2017).  
Moreover, the short chain fatty acids produced by fermentation of fiber in the gastrointestinal tract, 
acetate, butyrate and propionate are known to have an important function in controlling the 
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prevalence of specific skin microflora description, which later have an effect on the skin immune 
defence processes (Shu et al., 2013). Propionic acid may display extreme levels of antibacterial activity 
against the most prevailing community-acquired methicillin-resistant Staphylococcus aureus 
(Samuelson et al., 2015). Certain bacteria strains which are symbiotic skin inhabitants namely S. 
epidermidis and P. Acnes are identified as the most tolerant species compared to the other skin 
microflora microbes. Overall, the study found encouraging evidence to support the theory of an active 
interactive system between the human gastrointestinal tract and the skin. 
The gut to skin co-operation theory formulated by Arck et al. (2010) mentioned a possible gut to brain 
to skin co-operation, hence, the advantages of oral prebiotics and skin probiotics is explored. 
Additionally, as well as the oral probiotic created for the human skin, a recent group of emollients and 
moisturisers involving lysates of bacteria e.g. Vitreoscilla filiformis or Lactobacillus have been created. 
The current probiotic invention has been constructed to help manage diseases of the human skin for 
example, acne or atopic dermatitis. It does this by re-establishing the epidermal barrier, the 
microbiota of the human skin and regulating the activation of innate immune defence system. 
1.4			S.	epidermidis	–	An	opportunistic	pathogen						
Nosocomial infections are 41% of the time caused by coagulase-negative Staphylococci. Little is known 
about S. epidermidis clonality, pathogenic capabilities including its virulence factors and the 
prevalence of antibiotic resistance genes such as, mecA, IS256, qacA/B, and icaAB (Mirzaei et al., 
2017). Moreover, it is an opportunistic pathogen, as it can only become pathogenic by breaching the 
host innate immune system (Brown et al., 2012; Yen & Papin, 2017). Staphylococci are commonly 
found on human and other mammals’ skin and mucous membranes. Although S. epidermidis is not 
likely to cause terminal disease, treatment for S. epidermidis infections have a very low successful rate, 
hence, a heavy burden on the public health system (Duell et al., 2012; Otto, 2012).  
S. epidermidis species show a high level of diversity with seventy-four identified sequence types (ST). 
The clonal complex entails many of the identified isolates, this includes the most commonly found ST2 
isolate (Espadinha et al, 2019). Every ST2 isolate comprises of IS256 insertion sequences and ica genes 
which aid ST2 to spread successfully and S. epidermidis to be invasive (Mirzaei et al., 2017). Many of 
the ST2 isolates have the in vitro ability to allow S. epidermidis to form biofilms. There is information 
available on S. epidermidis genome, this includes biofilm-negative ATCC122288 and the biofilm-
positive clinical isolate RP62A9 (Grice & Segre, 2011; Espadinha et al., 2019).  
 
There is little evidence available on the lifestyle of the opportunistic pathogen S. epidermidis, 
however, S. epidermidis has recently attracted a lot of attention due to its infectious capabilities 
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(Brown et al., 2012).  Coagulase-negative Staphylococci (CoNS) group differentiates Staphylococcus 
aureus with other less or non-infective Staphylococci species (Zmantar et al., 2017). S. haemolyticus 
and S. epidermidis are a large part of the CoNS group amongst other nosocomial pathogens. 
Nevertheless, previous research on species identification for CoNS infections found that most of them 
were caused by S. epidermidis (Otto, 2012). S. epidermidis commonly causes infections through 
medical devices like central intravenous or peripheral catheters. S. epidermidis infections usually 
transfer from the skin of a patient, individual, practitioner or employee of health institutions through 
the inserting process of medical devices (Zmantar et al., 2017). High medical device usage directly 
correlates to the increasing number of S. epidermidis infections. Which are now known to report a 
minimum of 22% of bacteraemia in USA critical care patients, occurring in 4–5/1000 central 
intravenous catheter insertions (Espadinha et al, 2019; Sandoval-Motta & Aldana, 2016).  
There is a large amount of S. epidermidis on human skin with similar amounts colonising catheter 
surfaces (Mirzaei et al., 2017). Also, S. epidermidis are involved in vascular graft, ventriculoperitoneal 
medical device, surgical site, cardiac implant and prosthetic joint infection (Mansson et al., 2018). 
Finally, second to S. aureus, S. epidermidis has an increased percentage of intracardiac abscesses 
(38%), with 13% of prosthetic valve endocarditis (PVE) infections, and 24% mortality. Yet, PVE and 
other deadly infections are infrequent amongst S. epidermidis infections, overall S. epidermidis 
infections are characterised as mainly chronic and subacute (Mansson et al., 2018). 
Fundamental genetic or pathobiological differences in stratum corneum elements result in 
dysbacteriosis. Overall, affecting the colonising microbial population size and the diversity of species 
colonies. Imbalanced microbiota upsets the function of the epidermal barrier and intensifies long-
term skin illnesses including acne, psoriasis and eczema. For instance, S. epidermidis is a species 
inhabiting the human skin commensal microflora as an opportunistic pathogen within 
immunocompromised patients (Figure 3) (Brown et al., 2012; Conlan et al., 2012; Dreno et al., 2016). 
Why is it beneficial for S. epidermidis to have a low level of virulence and not cause life- threatening 
infections compared to the more virulence Staphylococcus species, S. aureus? It is assumed that S. 
epidermidis is more transmittable than S. aureus, based on a mathematical model formed by Massey 
et al. (2006). This model showed that avirulent variants out-competed virulent subtypes of 
Staphylococcal species. S. aureus has low asymptomatic transmission opposed to S. epidermidis high 
level of asymptomatic transmission. Massey et al. (2006) found that S. epidermidis broadly colonises 
human skin whereas S. aureus mostly colonises the nares region. They also found that S. epidermidis 
is a major part of the entire human population skin microflora in contrast to S. aureus species 
colonising few individuals. 
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Quorum sensing is a regulation of gene expression where the bacterial cell density influences bacterial 
gene expression (Figure 3 & 5) (Yan & Bassler, 2019). The bacterium must secrete an autoinducer and 
sense a signal via a regulatory receptor protein to communicate between cells. When there is a high 
level of microbial population density, autoinducers amass to a vital threshold value and induce the 
activation of certain genes and operons (Mirzaei et al., 2017). Quorum-sensing occurs in most 
bacteria, Staphylococci secrete post-translational modified protein named accessory gene regulator 
(Agr) (Espadinha et al, 2019; Hellmark et al., 2013) (Figure 5). There is a possibility of specific genetic 
influence on bacterial communication and colonisation (Figure 2) including quorum-sensing signals 
that cross-inhibit other microbes (Figure 2). Even though quorum-sensing system is advantageous to 
S. epidermidis species compared to S. aureus in vitro, there is no proof that it plays a part in vivo 
(Espadinha et al, 2019; Sandoval-Motta & Aldana, 2016). 
1.5	Agr	quorum-sensing	system	
Accessory gene regulator (Agr) and LuxS quorum-sensing systems are important for Staphylococcus 
intercellular interaction, biofilm growth and pheromone autoinducer peptide (AIP) production 
(Cheung et al., 2014). The Agr system consist of two operons that are from transcribed promoter P2 
and P3 to regulate bacterial cell density (Figure 5) (Cheung et al., 2014). AIP production starts in 
exponential phase of microbial growth (Mazhar & McAuliffe, 2014). The pheromone AIP is released 
by Staphylococci cell density and sensed by the same group of microorganisms, allowing the 
expression of biofilm formation. Throughout exponential growth phase the P2 and P3 promoter is 
switched off with low level of both operon transcription and AIP secretion due to promoter leakage 
(Figure 5A) (Mazhar & McAuliffe, 2014). The promoter P2 can transcribe a range of sensor proteins, 
including (1) a membrane transport protein (AgrB); (2) a AIP precursor (AgrD) which processes and 
exports AIP via transmembrane protein AgrB; (3) a membrane-spanning sensor (AgrC) is the cognate 
receptor of AgrD-induced AIP; and (4) a transcription factor (AgrA) that is possibly stimulated by AgrC 
(Cheung et al., 2014). When cell density growth increases, the bacteria population and extracellular 
AIP concentration also increases, hence, increasing the chance of AIP binding to cognate AgrC receptor 
(Figure 5B) (Mazhar & McAuliffe, 2014). Once AIP is bound to AgrC receptor, AgrA response regulator 
is activated, a process that comprises of dephosphorylation (Figure 5B). Activated AgrA (DNA-binding 
protein) bind to both promoters P2 and P3 in agr operon (agrBDCA), RNAII and RNAIII are then 
transcribed, respectively (Mazhar & McAuliffe, 2014). RNAII agrB, D, C, A genes are transcribed to 
encode AgrB, D, C, A, and RNAIII hld gene is transcribed to encode δ-hemolysin (also known as δ-toxin 
or δ-PSM). δ-Hemolysin is a haemolytic peptide which is a membrane-active protein toxic to 
eukaryotic cells. RNAIII controls gene expression through various methods, for example, repressing 
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translation by blocking mRNA from binding to its target site. Agr can also express exoproteins during 
stationary phase of growth (high cell density) (Cheung et al., 2014). 
 
 
Figure 5. A & B. Schematic diagram of Staphylococcus Agr quorum-sensing system (Mazhar & 
McAuliffe, 2014).  
The quorum-sensing system Agr is not very active however the system controls and expresses 
numerous hostile virulence factors, including the proinflammatory phenol-soluble modulins (PSM), 
psm genes are regulated by direct binding of AgrA to their promoters (Figure 5B) (Cheung et al., 2014). 
S. epidermidis are known to produce six PSMs that are all genome-encoded; PSMα, PSMβ1, PSMβ2, 
PSMδ, PSM𝜀, and δ-toxin.  After δ-toxin, β-PSMs (43–45 amino acid length) are the main types of PSMs 
found in S. epidermidis, they are the key players in biofilm formation (1.4) and detachment (see 1.5) 
(Cheung et al., 2010; Cheung et al., 2014). Enhanced production of β-type PSMs over α-type PSMs are 
observed in S. epidermidis during biofilm formation (Wang et al., 2011), but how differential 
production of α- versus β-type PSMs is attained systematically is unknown.  
There are physiological changes in biofilms of S. epidermidis and within the quorum-sensing agr 
system that protects the bacteria via two mechanisms (Siddhiqui et al., 2018).  Firstly, S. epidermidis 
sensitivity level is decreased for destructive substances including cytokines, antimicrobial molecules 
and antibiotics (Hellmark et al., 2013). The second mechanism is to stop the destructive molecule from 
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being hostile and switch it to a harmless state, this reduces inflammation and stops the host immune 
system from identifying the pathogen. Hence, the host defence system is completely evaded by S. 
epidermidis, the S. epidermidis biofilm appear to be dependent on several physiological alterations. 
This underlines the significance of S. epidermidis biofilm being able to evade host defence system 
during cutaneous colonisation and biofilm related infections (Siddhiqui et al., 2018). 
The acquired immune system comprises of highly specific systemic cells and processes to eliminate S. 
epidermidis colonisation. Nevertheless, there is not much information on how the acquired immune 
system can achieve this specifically for pathogenic S. epidermidis (Espadinha et al, 2019; Mirzaei et al., 
2017). One way how S. epidermidis may go unidentified and remain protected from antibodies is by 
using exopolymers (Cheung et al., 2010).  Some studies suggest that the host immune system may 
have evolved to react in a symbiotic way to colonising microbes (Hooper et al., 2012; Belkaid & Hand, 
2014; Le et al., 2018).   
1.6	Sensing	of	antimicrobial	peptides	(AMPs)	 
The most important biotic function antimicrobial peptides (AMPs) play in vivo is killing pathogens, 
including Gram-negative and -positive bacteria, viruses and fungi. Gene expression can occur in 
various host cells such as mucosal epithelial cells and phagocytic cells to encode AMPs (Marquette & 
Bechinger, 2018). Cytokines and pathogenic microbes induce gene expression to closely regulate host 
defense response. S. epidermidis cause bacterial lipid membrane leak and collaborate with human 
AMPs production to decrease the number of these microbes. These AMPs are vital cooperating signals 
between the host defence system and the microbiome. Almost thirty percent of the transcriptome of 
general epithelial cells use this process to communicate. 
There are two main groups that AMPs belong to, cathelicidins and defensins. The AMPs from these 
groups with an overall positive charge are called cationic antimicrobial peptides (CAMPs). However, 
an anionic AMP with a negative net charge has been detected from human sweat called dermcidin. 
(Espadinha et al., 2019). S. epidermidis, the Gram-positive bacteria has been found to have an AMP 
sensor. The recently identified AMP sensor is made up of three crucial factors, ApsS with a sensory 
function, ApsR the regulator and ApsX the unique final constituent of unidentified purpose. 
(Vasilchenko et al., 2019) 
As AMPs are the main element of the host innate defence system, to protect the bacteria from AMPs, 
the bacteria can utilise enzymes such as SepA protease, poly-N-acetylglucosamine (PNAG or PIA 
polysaccharide intercellular adhesin) and poly-γ-glutamic acid (PGA) (See 1.7.3) (Mirzaei et al., 2016; 
Espadinha et al, 2019). The skin has an environment of extensive mechanical stress making it 
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important for Staphylococci to have biofilm-related proteins and PIA (Mirzaei et al., 2017). PIA is a 
glycan of beta-1,6-linked 2-acetamido-2-deoxy-D-glucopyranosyl residues of which 15 % are non-N-
acetylated. (Spiliopoulou et al., 2012; Hofferek, 2019). These proteins are vital for colonisation and 
infecting the host as both commensal and pathogenic S. epidermidis strains, both type of strains have 
the same MSCRAMMs (microbial surface components recognising adhesive matrix molecules) (See 
1.7.2) (Geoghegan et al., 2010). This indicates that S. epidermidis can be viewed as an accidental 
pathogen and it is clinically important to research adherence and evasion of host immune system as 
this can be valuable for killing pathogenic bacteria and treating long-term infections (Espadinha et al., 
2019). 
Just the way human innate immune system recognises S. epidermidis pathogen associated molecular 
pattern (PAMPs), S. epidermidis also identifies dangerous foreign molecules produced by the human 
host (Joo et al., 2015). There is an AMP-sensing system within S. epidermidis named Aps. Diverse 
number of AMPs activate Aps system and cause an up-regulation of AMP-defensive systems. AMP-
defensive systems may include VraFG proteins, lysylation of phospholipids by the MprF enzyme and 
D-alanylation of teichoic acids (Joo, & Otto, 2015). This affects the exterior of the bacteria as it 
diminishes the negatively charged surface and halts the attraction of positively charged AMPs, 
efficiently exporting AMPs from the cytoplasm membrane (Figure 8) (Lin et al., 2018). Hence, Gram-
positive bacteria Aps system plays a similar role to Gram-negative AMP sensor named PhoP/PhoQ, 
however, the bacteria is not genetically related (Lin et al., 2018; Joo & Otto, 2015). The bacteria S. 
epidermidis Aps system is activated and limited to cationic AMPs (Lin et al., 2018). Aps system is a 
three-component regulator, it has an important component of unidentified function namely, ApsX 
(Joo et al., 2015). The response regulator protein ApsR (GraR) and histidine kinase ApsS (GraS) make 
up the other two components of the Aps system (Figure 8) (Joo et al., 2015).  
1.7	Biofilm		
Many microorganism cells produce and emit extracellular substances in the form of a slime layer, thus 
creating a hydrophobic biofilm. Biofilms are complicated multicellular assemblage of microbes 
adhered to a surface (Chua et al., 2014). This allows the microbe to adhere to different kind of surfaces 
including metals, plastics and the human body. The gene icaADBC is responsible for the coding of PIA 
and the polysaccharide capsule used in developing biofilm (Qin et al, 2016). The S. epidermidis biofilm 
is made up of groups of cells rooted in extracellular slime material which is hundred and sixty 
micrometres dense with over fifty cells. The S. epidermidis skin biofilm perform as a diffusion barrier 
to host defence mechanisms and antibiotics (Salgueiro et al., 2017). 
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It is important that ica operon express polysaccharides to form biofilms (Chua et al., 2014; Mirzaei et 
al., 2017). Some researchers have proposed that polysaccharide adhesin is efficient for adherence and 
cell to cell communication during the assembly process of biofilm production (Franca et al., 2016). 
Other researchers have suggested that adhesion is induced by microbial cell surface proteins and 
polysaccharides can only control the process of accumulating cells (Guo et al., 2019). 
Many microorganism cells produce and emit extracellular substances in the form of a slime layer, thus 
creating a hydrophobic biofilm. Biofilms are complicated multicellular assemblage of microbes 
adhered to a surface (Chua et al., 2014). This allows the microbe to adhere to different kind of surfaces 
including metals, plastics and the human body. Adherence to medical devices including catheters, 
mostly occur due to hydrophobic external layer of bacteria (Figure 6). Certain proteins promote S. 
epidermidis adhering to surfaces, this largely involves surface protein AtlE, which has two functions; 
to adhere to cells or surfaces and breakdown the cell-wall peptidoglycan of S. epidermidis (Mirzaei et 
al., 2017; Chua et al., 2014). Another protein named Bap/Bhp protein probably promote the 
hydrophobicity level of the bacteria cell outer layer. S. epidermidis mostly cause prosthetic joint 
infections, when the bacteria accumulate on an implant surface it creates a biofilm and transitions to 
a stationary phase in bacterial growth due to increased microbial populace densities (Mansson et al., 
2018).  During the stationary phase the bacteria grows slowly compared to planktonic bacteria, the 
bacteria has decreased metabolic activity and, thus, high level of resistance to elimination by growth-
dependent antibiotics, e.g. cell-wall-active antibiotics (Figure 6) (Spiliopoulou et al., 2012; Hellmark et 
al., 2013). Additionally, the biofilm decreases the penetrability of antibiotics and host immune 
components such as complement and antibodies (Figure 6) (Stipetic et al., 2016). 
It is important that ica operon express polysaccharides to form biofilms (Chua et al., 2014; Mirzaei et 
al., 2017). The gene icaADBC is responsible for the coding of PIA and the polysaccharide capsule used 
in developing biofilm (Qin et al, 2016). The S. epidermidis biofilm is made up of groups of cells rooted 
in extracellular slime material which is hundred and sixty micrometres dense with over fifty cells. The 
S. epidermidis skin biofilm perform as a diffusion barrier to host defence mechanisms and antibiotics 
(Salgueiro et al., 2017). Some researchers have proposed that polysaccharide adhesin is efficient for 
adherence and cell to cell communication during the assembly process of biofilm production (Franca 
et al., 2016). Other researchers have suggested that adhesion is induced by microbial cell surface 
proteins and polysaccharides can only control the process of accumulating cells (Guo et al., 2019). 
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1.7.1	Biofilm	formation	
A biofilm is formed when it adheres to a surface, thereby accumulating cells to form a multi-layered 
structure (Figure 6) (Hellmark et al., 2013). Hence, for biofilm growth it is important to have adhesive 
agents for the colonisation of surfaces and for the cells to communicate between each other. Biofilm 
disruption is required to form fluid-filled channels which are important for the delivery of nutrients to 
all biofilm cells and allows mature biofilm to have the usual 3D shape (Figure 6 & 7) (Franca et al., 
2016). Disruption is also required in the detachment of cell aggregations from the biofilm, this restricts 
the biofilm from expanding and leading to the spread of infection (Figure 6 & 7). Once the biofilm 
adheres to a surface, it grows through an intercellular aggregation process which is induced by a 
diverse variety of surface macromolecules (Chua et al., 2014). Commonly, exopolysaccharide and few 
proteins mainly focus on forming the extracellular biofilm matrix. Additionally, extracellular DNA from 
lysed cells and teichoic acids may have an accessory role in intercellular aggregation and they are 
mostly reliant on their polyanionic disposition (Chua et al., 2014). 
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Adherence to medical devices including catheters, mostly occurs due to hydrophobic external layer of 
bacteria (Figure 6 & 7). Certain proteins promote S. epidermidis adhering to surfaces, this largely 
involves surface protein AtlE, which has two functions; to adhere to cells or surfaces and breakdown 
the cell-wall peptidoglycan of S. epidermidis (Chua et al., 2014; Mirzaei et al., 2017). Another protein 
named Bap/Bhp protein probably promote the hydrophobicity level of the bacteria cell outer layer. S. 
epidermidis mostly cause prosthetic joint infections, when the bacteria accumulate on an implant 
surface it creates a biofilm and transitions to a stationary phase in bacterial growth due to increased 
Figure 6. Steps of Biofilm Formation (Monroe, 2007; Aguinaldo, 2015): 
1. Bacteria adhere to a surface  
2. Bacteria cells replicate and form a single thick polysaccharide matrix layer. Biofilm is 
not visible at this stage. 
3. A 3D biofilm structure is formed by large bacterial colonies secreting 
exopolysaccharide and quorum-sensing. 
4. The exopolysaccharide slime protects the bacteria from harsh environment, 
antibiotics, toxic chemicals etc. Nutrients are diffused through the matrix.  A 
secondary bacterial species joins the biofilm. The small proximity between both 
species allows genetic exchange. 
5. Depletion of oxygen and nutrients. Due to shear force the planktonic (free-floating) 
bacteria cells disperse for recolonisation.  
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microbial populace densities (Mansson et al., 2018).  During the stationary phase the bacteria grows 
slowly compared to planktonic bacteria, the bacteria has decreased metabolic activity and, thus, high 
level of resistance to killing by growth-dependent antibiotics, e.g. cell-wall-active antibiotics (Figure 6 
& 7) (Spiliopoulou et al., 2012; Hellmark et al., 2013). Additionally, the biofilm decreases the 
penetrability of antibiotics and host immune components such as complement and antibodies (Figure 
6 & 7) (Stipetic et al., 2016). 
1.7.2	MSCRAMMS	
Matrix proteins within the bacteria rapidly envelope abiotic surfaces such as those present in medical 
equipment. S. epidermidis has a large variety of surface proteins that are part of a group named 
'microbial surface components recognising adhesive matrix molecules' (MSCRAMMs) and they can 
potentially communicate with matrix proteins. The MSCRAMMs are likely to have a covalent-bond 
between them and the microbial exterior via sortase A (Geoghegan et al., 2010). However, 
MSCRAMMs may be non-covalently bound to the microbial surface polymers e.g. teichoic acids, this 
concept is yet to be completely understood (Geoghegan et al., 2010). The protein SdrG have been 
observed to have a covalent bond with fibrinogen and the protein SdrF is covalently bound to collagen 
(Faustino et al., 2013). Moreover, autolysins Aae and AltE interact non-specifically and have a non-
covalent bond with fibrinogen, vitronectin and fibronectin (Salgueiro et al., 2017; Becker et al., 2014).   
S. epidermidis are able to express three variety of proteins related to the cell surface, namely SdrG, 
SdrF and SdrH, these involve repeats of serine-aspartate dipeptide (Faustino et al., 2013). The cell 
surface proteins SdrG and SdrF structure and sequence are almost indistinguishable when compared 
to the Sdr protein of S. aureus, the proteins encompass exceptional 625- and 548-residue A regions at 
the N termini, succeeded by 110-119-residue B-repeat regions and SD-repeat regions (Faustino et al., 
2013). The C termini comprises of hydrophobic amino acid molecules distinctive of cell surface 
proteins covalently bound to peptidoglycan and LPXTG motifs. However, SdrH comprise small 60-
residue A region at its N terminal succeeded by a region with SD-repeats, it has a specific 277-residue 
C region and a C-terminus hydrophobic fragment. SdrH lack a LPXTG motif (Faustino et al., 2013). 
The most commonly researched MSCRAMM of S. epidermidis is a protein which binds to fibrinogen 
namely SdrG (Fbe), it belongs to the aspartate/serine repeat family (Geoghegan et al., 2010; Becker 
et al., 2014). The three main proteins from the aspartate/serine family exist in several S. epidermidis 
strains including SdrG, SdrF and SdrH. In vitro, SdrG is known to be important and enough to encourage 
S. epidermidis to adhere to fibrinogen, also in vivo SdrG assists central venous catheter-related 
infection (Salgueiro et al., 2017; Faustino et al., 2013). SdrG can bind to the thrombin cleavage site in 
the beta chain of fibrinogen via the 'dock, lock and latch' system (Becker et al., 2014; Faustino et al., 
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2013). This process is meant to cause a highly stable MSCRAMM-substance communication 
(Geoghegan et al., 2010). This emphasises the significance of SdrG assisting S. epidermidis in causing 
infections, also, there is an increase in the expression of SdrG in an in vivo condition with antibodies 
to SdrG are identified in human blood (Faustino et al., 2013). Not long ago, SdrF has been found 
promoting infection by encouraging S. epidermidis to adhere to ventricular medical devices. 
Additionally, various other S. epidermidis MSCRAMMs are yet to be identified and undergo 
characterisation to understand the function they play in matrix protein binding process and the 
pathogenicity of S. epidermidis (Geoghegan et al., 2010). 
1.7.3	PNAG/PIA	
Several strains of S. epidermidis create a PNAG homopolymer also known as PIA, which surround and 
adheres S. epidermidis cells within a biofilm (Mirzaei et al., 2016; Spiliopoulou et al., 2012). This 
protein molecule is different to poly-N-acetylglucosamine polymers observed in flora, for example 
chitin, this is due to its β 1–6 connection. Recently, PIA/PNAG has also been found in several other 
microbes such as Yersinia pestis and Escherichia coli. Biosynthesis of PIA/PNAG is vital for formation 
of biofilm in vitro and it has a substantial influence on S. epidermidis infection in animal models 
(Spiliopoulou et al., 2012). The process of PIA/PNAG production is initiated by a product of a gene 
namely intercellular adhesion (ica) locus (Mirzaei et al., 2016). A chain of reaction from activated N-
acetylglucosamine monomers, is formed by IcaD and IcaA where the prolongation relies on the IcaC 
protein, this is possibly due to the exporting role it is known to play. Once exportation occurs, partial 
de-acetylation of the N-acetylglucosamine residues is completed by the enzyme IcaB, which is situated 
on the surface of the cell. Due to de-acetylation the neutral polymer becomes positively charged, this 
allows PIA/PNAG to bind to surfaces and for it to play a part in numerous biotic interactions, such as 
S. epidermidis evading the host immune defence system (Spiliopoulou et al., 2012). Several universal 
virulence regulators influence the formation of PIA/PNAG excluding the quorum-sensing regulator agr 
(Figure 5). Although there is limited understanding on what environmental signals regulate the 
expression of PIA/PNAG, especially in vivo, the intricacy of regulation reinforces the significance of 
PIA/PNAG for S. epidermidis physiopathology (Mirzaei et al., 2016).  
PIA/PNAG has recently been identified to be insignificant when forming biofilms in all S. epidermidis 
species (Spiliopoulou et al., 2012). This is because S. epidermidis strains isolated from biofilm related 
infections appeared to not have ica genes (Mirzaei et al., 2017). Distinct surface proteins involving 
biofilm-associated protein (Bap/Bhp) and accumulation associated protein (Aap) may induce or 
predominantly form biofilm in certain strains of S. epidermidis. The Aap protein demands zinc ions and 
proteolytic activation to promote the production of the biofilm. Zinc ions are vital for modular 
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association of G5 tandem repeats, this underlines that Aap forms fibril-type structures on the 
microbial outer layer. These domains are seen interacting with N-acetylglucosamine and may possibly 
bind to PIA/PNAG to form a polysaccharide/protein biofilm system (Mirzaei et al., 2016). A chelating 
agent was used to prevent the production of biofilm in vitro, the result highlighted that strong biofilm 
forming strains such as S. epidermidis RP62A strain are completely reliant on Aap (Otto, 2009). 
Additionally, monoclonal antibodies produced against Aap stopped S. epidermidis RP62A from forming 
biofilm. Nonetheless, the findings from this report contradicted another report which did not find any 
protein that induced biofilm formation in the identical strain. Hence, certain proteins may contribute 
to S. epidermidis forming biofilms, however this requires further investigation. Finally, the concept of 
biofilms being produced only by proteins is not robust as the one on PIA/PNAG that demonstrates 
both exopolysaccharide and proteins are required to promote S. epidermidis biofilm production. 
The overall information on molecular processes of S. epidermidis regulation and production of biofilm 
is nearly completely reliant on in vitro study (Franca et al., 2016). Animal models have been used to 
contribute to the pathogenesis of S. epidermidis by demonstrating few factors including PIA/PNAG, 
Fbe, AtlE, SdrF, SdrG and regulators Agr, sigB and luxS (Mirzaei et al., 2017; Pereira et al., 2018). 
Additionally, there is evidence signifying the importance of expressed biofilm elements, in vivo. 
However, there is an imperative requirement for more comprehensive in vivo studies to provide 
complete understanding of S. epidermidis biofilm related infections (Franca et al., 2016). 
1.7.4	Biofilm	in	host	evasion	
Biofilm has a distinctive composition and construction for the development of biofilm resistance to 
numerous antibiotics and evasion of host defence systems (Franca et al., 2016). S. epidermidis show a 
large variety of genetic variations throughout the biofilm growing process, this includes down-
regulation of basic cell mechanisms, for example, nucleic acid, protein biosynthesis and cell wall 
(Franca et al., 2016). The regulation of gene expression may alter and lead to the inactivity of several 
antibiotics which target against S. epidermidis developing biofilm cells, these involve antibiotics such 
as, quinolones, aminoglycosides and penicillin (Hellmark et al., 2013). 
S. epidermidis is unaffected by the harsh surroundings that usually occur in its natural habitat due to 
the genes the bacteria may possess. For instance, S. epidermidis can survive extreme salt and osmotic 
pressures via six transport systems for osmoprotectants and eight sodium ion / proton exchangers 
(Dreno et al., 2016). There are only few known bacteria that can withstand high salt concentrations or 
other extremities on human epithelia, other than S. epidermidis. The ability to form biofilms help the 
bacteria to survive harsh conditions significantly. Over the years a large amount of osmoprotective 
elements have been expressed and reported in S. epidermidis biofilms (Mirzaei et al., 2017). 
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Furthermore, the bacteria must survive host immune defence attacks, especially antibacterial 
peptides. β-defensin is one of the key antibacterial peptides found mostly at epithelial surfaces. Gram-
positive bacteria can act as a chemo-attractant between innate and acquired immune systems 
(Siddhiqui et al., 2018). 
	
  
Figure 7. S. epidermidis biofilm structure and function in host immune evasion. The biofilm matrix is 
made up of PIA/PNAG, Aap, Bap/Bhp, extracellular matrix binding protein (Embp), extracellular DNA 
(eDNA) and teichoic acids. Biofilm channels are produced by PSMs, which eventually cause cell cluster 
detachment and overall dissemination of the biofilm. PSMs also play a role in bacteremia and sepsis 
in immunocompromised individuals. Both biofilm structure and matrix provide protection from host 
defences such as opsonising immunoglobulins binding, complement components and AMPs. 
Furthermore, there is a drastic reduction in leukocytes attacks (Le et al., 2018). 
Brandwein et al. (2016) isolated Staphylococcal strains from hospital settings and patient body sites, 
Staphylococcus aureus biofilm was found in atopic dermatitis lesions on patient skin sites. Once S. 
epidermidis penetrates through the stratum corneum it must evade the host defence processes by 
changing its own mechanisms (Brandwein et al., 2016).  S. epidermidis biofilm adapts to the host 
immune system and alters its bacterial gene expression involving a decreased metabolism, low 
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transcription and translation as well as a switch from the aerobic system to fermentation to produce 
energy (Allen et al. 2014). These alterations are possibly due to the reduced level of oxygen within the 
biofilm and the limited amount of nutrition available. Notably, this causes the biofilm to become 
dormant and enter the stationary phase of growth, thereby, the antibiotic used against the biofilm 
becomes ineffective as the biofilm now has low sensitivity for the antibiotic treatment (Brandwein et 
al., 2016). Likewise, the biofilm is capable of evading the host defence mechanisms as cytokines and 
antibiotics mainly rely on highly functional cell metabolism and cell-development mechanisms.  
 
1.8	 Biofilm	detachment		
Unlike the intercellular accumulation phase, there is little understanding of S. epidermidis biofilm 
structure and the process of detachment. It is commonly known that S. epidermidis biofilm 
detachment is regulated by the Agr quorum sensing mechanism (Pereira et al., 2018). Biofilms that 
are not controlled by Agr due to dysfunction are a lot denser and display clear deficiencies during 
detachment (Boles & Horswill, 2011).   A model that had Agr expressed in the outer surface of biofilm 
was known to encourage cluster of cells detaching from the biofilm surface, hence, regulating biofilm 
dissemination (Pereira et al., 2018).  Similarly, the function of Agr in S. epidermidis is restricted to the 
exposed surfaces of a biofilm, this suggests that both closely related Staphylococci species share the 
same quorum-sensing system to control the detachment of biofilm (Pereira et al., 2018).  The 
mutation of both Agr system or psm genes, can support the formation of compact biofilms (Wang et 
al., 2011), however, the biofilm can no longer detach and form biofilm elsewhere (Joo and Otto, 2012). 
 
There are two known processes of biofilm detachment, one of them include the enzymatic breakdown 
of proteinaceous biofilm elements (exopolymers) and the second process is disrupting the non-
covalent interactions by utilising surfactant-like substances. The first process has been observed in S. 
aureus, nevertheless, no evidence has been observed where enzyme is degrading exopolymers in S. 
epidermidis to promote biofilm detachment. Nonetheless, S. epidermidis produce lots of exoproteases 
that have little to none substrate specificity, they may possibly breakdown exopolymers (Boles & 
Horswill, 2011). On the other hand, Staphylococcal strains lack specific enzymes to degrade 
exopolysaccharide such as PIA/PNAG, whereas, many other microorganisms that produce PIA/PNAG 
are able of degrading their exopolysaccharide. Furthermore, surfactant-like substances disrupt non-
covalent hydrophobic and electrostatic interactions. An example of a non-covalent interaction is the 
cationic PIA/PNAG interacting with anionic exopolymers or the interaction between the hydrophobic 
areas of the microbial outer layer. The small amphipathic PSMs including S. epidermidis delta-toxin 
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are suggested to have this detachment mechanism (Boles & Horswill, 2011). S. epidermidis 
exoproteases and PSMs are strongly controlled by Agr, thus, supporting the concept of exoproteases 
and PSMs having a function in organising the structure of the biofilm (Cheung et al., 2014; Boles & 
Horswill, 2011).   
1.9	Protective	exopolymers													
S. epidermidis and Bacillus anthracis are the only species known to date where PGA plays a role in the 
spread of disease. Additionally, PGA encourages S. epidermidis to grow in high salt concentrations 
(Chua et al., 2014). Numerous halophilic microorganisms PGA have similar function that contribute to 
osmotolerance and PGA also promote S. epidermidis colonisation. Also, cap genes are increasingly 
expressed during biofilm growth. Remarkably, PGA exist in several CoNS, but is missing in S. aureus 
(Cave et al, 2019). 
Furthermore, exopolysaccharide PIA/PNAG can also protect S. epidermidis from human host defence 
mechanisms such as AMPs, neutrophil phagocytosis, immunoglobulins and complement deposition. 
Positively charged PIA/PNAG protect S. epidermidis from AMPs with either negative or positive charge, 
this indicates that the activity of PIA/PNAG may not be restricted to electrostatic repulsion of AMPs 
with identical charge (Yan & Bassler, 2019).  
1.10	Pathogen-associated	molecular	patterns		
Pathogen associated molecular pattern (PAMPs) are substances displayed on the bacteria exterior 
layer, the host innate defence system can identify PAMPs as a foreign molecule via pathogen 
recognition receptors (PRRs) such as TLRs (Noreen et al., 2015). PAMPs identification leads to the 
activation of host defence response for example, cytokine is secreted, and phagocytosis occurs. Similar 
to most Gram-positive bacteria, S. epidermidis PAMPs are lipoteichoic acids and lipoproteins. 
Additionally, S. epidermidis have specific unique molecules such as PIA/PNAG which activate the host 
innate defence mechanism by activating the Toll-like receptor 2 (TLR2) (Noreen et al., 2015). S. 
epidermidis uses PIA/PNAG for host immune evasion by evading PRRs. For instance, it is observed that 
PIA/PNAG stimulate the Toll-like receptor 2 (TLR2) (Noreen et al., 2015). Nevertheless, this has yet to 
be confirmed with deletion mutant genomes, also TLR2 stimulators could have been misidentified due 
to contaminated lipoproteins (Yan & Bassler, 2019). Identification of PIA/PNAG by the host defence 
mechanism plays a fascinating role of hide-and-seek between the host and the invading bacteria, as 
S. epidermidis uses the molecule for host immune evasion while stimulating the innate immune 
defence system. 
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It is imperative to know that lipoproteins were the foundation of the study, which is a strong pro-
inflammatory contaminant that may result in incorrect identification of TLR2 stimulants (Noreen et 
al., 2015). Likewise, pro-inflammatory capabilities of S. epidermidis PSMs are yet to be verified using 
gene deletion mutation or synthetic peptides (Otto, 2014). Nonetheless, the similitude of the 
confirmed function of S. epidermidis and S. aureus PSMs show that the detailed pro-inflammatory 
influence of S. epidermidis PSMs is authentic; however, the activation of TLR2 by PSMs require 
confirmation (Cheung et al., 2014; Noreen et al., 2015). Lastly, an abnormal short-chain pro-
inflammatory lipoteichoic acid has been observed in S. epidermidis. On the other hand, the chemical 
characterisation of the purified element has no indication of teichoic acid-associated polymer, and 
hence the character of this substance and the reported pro-inflammatory function require 
confirmation. Thereby, further research is needed for characterisation of S. epidermidis substances 
that stimulate the host immune defence system. 
1.11		Evasion	of	host	defences		
A pathogen must evade the human body host defence in order to withstand and cause disease. Few 
host defence systems exist, for example, AMPs on the skin. S. epidermidis must survive other host 
defence responses once it breeches the epithelial barrier. Invading microbes as well as S. epidermidis 
interact with the innate immune system in an unspecified way. The colonising S. epidermidis bacteria 
have numerous mechanisms to avoid being ingested and killed by neutrophils while also evading 
AMPs.  
A pathogen must evade multiple human body natural defences for survival (Otto, 2009). There is 
limited subset of mechanisms of host defence mechanisms existing on the human skin. S. epidermidis 
must avoid AMPs and survive several other defence mechanisms after penetrating the epithelial 
barrier (Whitney et al., 2010). The innate immune system reacts without being specific to any microbe 
entering, including S. epidermidis (Cheung, et al., 2010).  The innate immune system mainly reacts by 
ingesting microbes using neutrophils, eradicating them with AMPs and reactive oxygen species (Otto, 
2009). S. epidermidis can avoid being ingested and killed by neutrophils via AMPs resistance 
mechanism (Figure 6) (Le et al., 2018).  
The function of the acquired immune system during S. epidermidis infection is not well understood. 
The human immune system has difficulty killing lifelong S. epidermidis infection regardless of the 
creation of antibodies for S. epidermidis exopolymers. This shows that the acquired immune system 
is ineffective in destroying S. epidermidis biofilm. S. epidermidis polymers including PIA/PNAG and PGA 
may cause this, these exopolymers shelter the bacteria from antibody recognition and other 
important mechanisms of innate host defence. Even with low production of pseudopeptide polymer 
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PGA, the gene product of cap locus is imperative for S. epidermidis protection from AMPs and 
neutrophil phagocytosis. Furthermore, the host defence system may have adapted overtime to not 
have a strong response against predominant infectious pathogens.  
 
1.11.1	AMP	Resistance	
 
Figure 8. A general demonstration of Staphylococcus becoming resistant to AMPs (Joo & Otto, 2015).  
AMP hBD3 is an important part of the innate immune system on the epithelial. S. epidermidis can 
develop resistance to AMPs by inducing hBD3 in order to control the three main genes dltB, vraF and 
mprF (Cheung et al., 2010). Human host cells mainly generate positively charged AMPs (CAMPs, green 
in diagram) and sometimes negatively charged AMPs (red in diagram), e.g. dermcidin. CAMPs 
stimulate the Aps/VraFG regulatory system to cause an amplification in Dlt system expression. The dlt 
operon D-alanylates both teichoic acid and MprF, thus, altering lysyl-phosphatidylglycerol. Due to 
these modifications the cell wall repulses CAMPs or has a low attraction for CAMPs (Figure 8). 
Aps/VraFG also stimulates VraFG expression, this could possibly involve AMP export. PSM ABC 
transporter export membrane active AMPs e.g. Staphylococcal PSM toxins and maybe AMPs produced 
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by the host from the cell membrane (CM). The exported proteases that have little substrate 
specificity tend to destroy both anionic AMPs and CAMPs, regulated by global regulators such as Agr 
and Staphylococcal accessory regulator (SarA) (Figure 8). PSMs and other toxins are degraded by 
aureolysin, a protease which is also regulated by multiple global regulators, including Agr and SarA.  
CAMPs are inactivated by staphylokinase, through a sequestration process. This method is observed 
in surface polymers that have an opposite charge to AMPs e.g. positively charged PIA 
exopolysaccharide sequestrating negatively charged AMPs. The production of a biofilms adds to AMP 
resistance through various methods such as reduced penetration. Additionally, the cationic biofilm 
PIA may repulse CAMPs (Figure 8) (Joo & Otto, 2015). 
1.11.2	PSMs	
 S. epidermidis as well as all the other Staphylococci species including the pathogenic S. aureus contain 
genes encoding PSMs and other related peptides (Cheung et al., 2014). These are both hydrophilic 
and hydrophobic helix shaped small peptides. PSMs are a group of virulence toxins that are soluble 
in phenols and may contribute to the pathogenicity of S. epidermidis (Otto, 2014). Although, PSMs 
commonly lack bacteriostatic characteristics (Cheung et al., 2014). AMPs as well as PSMs of alpha-
type (20–25 amino acids) are cationic, whereas beta-type PSMs (43–45 amino acids) have a net anionic 
charge (Cheung et al., 2010). The amphipathic α-helix nature of PSMs allow it to have an affinity for 
lipids, hence, α-type PSMs are more active against eukaryotic cells compared to prokaryotic cells. 
PSMs with big hydrophobic side chains prevent antibacterial activity by avoiding microbial membrane 
disruption. Cheung et al., (2014) findings showed that PSMs can have a different effect on prokaryotic 
cell membrane compared to eukaryotic cells. The α-type PSMs can lyse human cells such as 
erythrocytes and leukocytes while promote inflammatory responses (Cheung et al., 2014). 
 
1.12	Pathogenicity	
It is important for most pathogens to produce toxins to be more virulence such as S. aureus. Although, 
S. epidermidis is considered avirulent and a non-enterotoxin producer, Pinheiro, et al. (2015) identified 
enterotoxin genes within S. epidermidis. Pinheiro, et al. (2015) reported that the most identified 
common enterotoxin genes were sea (53.3%), seg (64.5%) and sei (67.5%). Also, the seg gene in S. 
epidermidis had a positive correlation (p = 0.02) with high toxicity levels. The agr group II is possibly 
linked to S. epidermidis producing enterotoxin C, which increases the pathogenicity of S. epidermidis 
variants identified from blood samples, which then leads to severe cases of sepsis (Pereira et al., 2018). 
However, compared to the large production of toxins by S. aureus, S. epidermidis produce few toxins, 
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the major toxin it does produce are namely PSMs. All S. epidermidis produce PSMs except S. 
epidermidis strains with natural agr dysfunction (Pereira et al., 2018). PSMs are typically α-helical, 
short and amphipathic (Cheung et al., 2014) and sometimes have cytolytic function but mainly pro- 
inflammatory function. S. epidermidis produce PSMγ/ δ-toxin (a 24-amino acid peptide) and S. aureus 
produces a similar peptide but the positioning of one amino acid varies from the S. epidermidis 
homologue (Cheung et al., 2014). Several reports have found that S. epidermidis PSMγ assist in 
necrotising enterocolitis in new-borns. Few S. aureus PSMs have similar function as S. epidermidis 
PSMs of lysing host neutrophils (Cheung et al., 2014). Nevertheless, S. epidermidis PSM production 
mostly constitutes of noncytolytic β-type and mild cytolytic PSMs (Otto, 2014). In conclusion, although 
S. epidermidis may lack highly virulence toxic molecules compared to S. aureus, due to the S. 
epidermidis PSM production, S. epidermidis has an evolutionary advantage over more virulence 
Staphylococci strains (Otto, 2014). Although S. epidermidis toxicity factor has been researched the 
process of toxicity is not well understood.  
Furthermore, other possible virulence substances produced by S. epidermidis are now being studied 
as well as the fibrinogen binding process (Becker et al., 2014). A gene called fbe consists of an open 
reading frame of 3,276 nucleotides which encode a protein named Fbe, which has a molecular weight 
of ~119 kDa (Salgueiro et al., 2017). Biomaterial implants are quickly inhabited by plasma substances 
and fibrinogen aid bacterial cells adhere to the biomaterial surface. A problem may occur when 
adhesion occurs on the identical regions of medical implant by pathogenic microorganisms, hence, 
causing infection (Salgueiro et al., 2017; Becker et al., 2014).  
 
1.13	Clinical	background	 
S. epidermidis commonly cause minor skin infections, for example, pimples and boils. These minor 
infections usually heal without the need for antibiotics. S. epidermidis typically infect patients in 
healthcare settings by adhering to hydrophobic biopolymers of prosthetics, hence, contaminating the 
equipment used for patient-care and colonising the environmental surroundings (Kleinschmidt et al., 
2015). Intravascular implants involving prosthetic heart valves and shunts may carry S. epidermidis 
biofilms and infect patients (Hellmark et al., 2013).  S. epidermidis can infect a large wound and 
contaminate catheters and prosthetic joints to enter the host bloodstream (Mansson et al., 2018). Pus 
secretion and high levels of inflammation may occur when a patient uses a contaminated catheter 
carrying S. epidermidis. This makes it tremendously painful for the patient to urinate. S. epidermidis is 
also known to cause illnesses such as septicemia and endocarditis (Onyango et al., 2018; Hellmark et 
al., 2013). 
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Septicemia or bacteraemia is the poisoning of the blood caused by infectious bacteria (Kleinschmidt 
et al., 2015).  Septicemia is a microbial infection in the bloodstream where the bacteria may enter 
through the urinary tract, skin or lungs. Septicemia tend to affect the weak immunocompromised 
neonatal, older individuals and patients that had surgery (Kleinschmidt et al., 2015). Septicemia is a 
life-threatening disease as the bacteria toxins spread through the bloodstream to the entire body, 
septicemia must be cured quickly in a healthcare facility, if it is left unchecked septicemia can develop 
into sepsis (Kleinschmidt et al., 2015). Septicemia symptoms include chills, fever, rapid respiration and 
fast heart rate. If septicemia is not treated properly or left untouched, the symptoms become more 
severe. These symptoms may include nausea, red marks on the skin, confusion, shock, lack of 
concentration and pass low volumes of urine. 
Endocarditis is the microbial colonisation of the inside the lining of heart muscles and heart valves 
(endocardium). Without proper early treatment, endocarditis may impair or destroy the heart valves 
that may lead to fatal complications. Endocarditis treatment mainly include the usage of antibiotics 
and sometimes surgery. People with artificial heart valves, damaged heart valves, or other heart 
defects are at a higher risk of developing endocarditis. Symptoms of endocarditis include, fatigue, 
aching muscles and joints chills, fever and night sweats, shortness of breath, swelling of feet, legs or 
abdomen and changed heart murmur (the sound of blood rushing through the heart). 
When Sahal & Bilkay (2014) examined blood samples from patients that had cardiovascular surgery as 
well as wound samples, S. epidermidis strains displayed a strong capacity to form biofilms (surgery 
samples 35% and wound samples 40%), 80% of them were resistant to β-lactam and 100% of them 
were multi antibiotic resistant (Sahal & Bilkay, 2014). The spread and quick growth of antibiotic 
resistant S. epidermidis microbe in healthcare settings are associated with certain factors for example, 
increased selective pressure, that occur due to improper and widespread use of antimicrobials mainly 
in hospitals. Moreover, there are other possible agents that cause dissemination of microbes, which 
may involve cross transmission amongst patients via inadequate infection and control strategies, 
bacterial mutation and horizontal resistance genes transfer along with an intricate relationship among 
nominated antimicrobial substances and microbial resistance. 
 
1.14	 Treatment							
S. epidermidis infected pus (from a boil or a pimple) is grown and tested against antibiotics in the lab 
to see which antibiotic kills the bacteria. An actual Staphylococci skin infection e.g. a boil may heal 
after ten to twenty days if it is not treated, but if it is treated with antibiotic then the healing process 
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speeds up. 80% of catheters infected with S. epidermidis are treated with antibiotics including 
vancomycin without removing the catheter. Two treatments that are frequently favoured in treating 
other microbes including S. aureus is decolonisation and vaccination, however these options are 
ineffective for S. epidermidis. Firstly, there is no vaccine available for S. epidermidis infections and lots 
of studies show that the use of traditional immunisation is problematic for Staphylococci infection. 
Secondly, S. epidermidis is a major part of the human microbiota, hence it is difficult for it to be 
eradicated, if S. epidermidis were to be destroyed, quick re-colonisation from other individuals can 
occur. By excluding S. epidermidis from the human microflora it may hypothetically lead to more 
aggressive pathogens replacing S. epidermidis. Therefore, it is generally agreed upon that the most 
effective way of reducing the number of S. epidermidis infections is by preventing the spread of S. 
epidermidis (Szemraj et al., 2019). This consists of medical equipment sterilisation, health care 
personnel in contact with indwelling medical devices during surgery and patient body parts 
sterilisation.  
It is a challenging burden on the healthcare system to treat infections linked to S. epidermidis biofilms. 
This is due to the bacteria being resistant to antibacterial molecules and the human immune defence 
mechanism (Hoiby et al., 2010). In addition to this, currently the occurrence of virulence microbial 
strains becoming resistant to several antibiotics is drastically rising. Thus, making it difficult to treat 
microbial infections which has quickly become the deadliest health threat to all humans (Guridi et 
al., 2015). This difficulty has mostly occurred due to the phenotypic resistance of microorganisms as 
they act as a ‘reservoir’ and harbour resistance genes in the bacteria chromosome and/or plasmid 
DNA. 
Lastly, França et al. (2016) findings raised significant consternation about the recent approach 
suggested on clearing S. epidermidis biofilm-associated infection. The most commonly proposed 
treatment for Staphylococci biofilm infections is to use enzymes that degrade matrix, for example, 
dispersin B has the capacity to disperse cells from Staphylococcal biofilms attached to a given surface. 
Nevertheless, the utilisation of enzymes that breakdown biofilm matrix or other molecules eventually 
cause disassembly of Staphylococcal biofilms (Boles & Horswill, 2011), this approach requires careful 
consideration as cells dispersed from the biofilm may increase inflammation in the host, therefore, 
increasing the level of disease (Franca et al., 2016). 
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1.15	Prevention	
Health care professionals should focus on carrying out preventive measures to reduce the incidence 
of S. epidermidis infections or to completely eliminate the bacteria (Perez & Patel, 2018). These 
practices involve controlling risk factors, for example reintubation, nasogastric and endotracheal 
tubes, tracheotomy, poor infection control and hand washing procedures among hospital employees, 
old antibiotic treatments, contaminated respiratory aids, water or drugs are effective means of 
preventing S. epidermidis infections (Perez & Patel, 2018). 
A small synthetic antimicrobial peptide called bactericidal peptide 2 (BP2) is shown to reduce 80% risk 
of acquiring S. epidermidis infection in the hospital via implants in a research carried out by (Perez & 
Patel, 2018). BP2 has strong bactericidal activity at micromolar concentrations for a broad spectrum 
of microorganisms, involving antibiotic-resistant bacteria. The staphylocidal activity of BP2 is not 
affected by physiological salt concentrations and is only slightly affected by the presence of human 
plasma (Simonetti et al., 2013). BP2 is more active than HNP1-3 and as active as LL-37, a highly potent 
human antimicrobial peptide. Unlike LL-37 (Mahlapuu et al., 2016) and HNP1-3 (Papot et al., 2017), 
the microbicidal activity of BP2 is not inhibited by physiological salt concentrations, stressing the 
potential of BP2. 
1.16				Antibiotics	
An antibiotic is a substance with a low molecular weight (<1000 daltons), for example antimicrobial 
substances (Aminov, 2010; Domínguez & Meza-Rodriguez, 2019). Initially, microbes generated 
antibiotics to stop other distinct microorganisms from growing. The word 'antibiotic' has a Greek 
origin, where 'anti' means 'against' and 'bios' translates to 'life', hence, 'against bacterial life' (Kumbhar 
& Watve, 2013). The sulfa antibiotic prontosil was the first antibiotic introduced in 1935, it functions 
as a metabolic precursor to inhibit the enzyme needed for biosynthesis of microbial DNA (Aminov, 
2010; Domínguez & Meza-Rodriguez, 2019).  Also, all fungi, microfauna and animals produce little 
peptides that function as antibiotics, namely AMPs. AMPs are the first line of host defence system for 
inhibiting colonising bacteria. Generally, AMPs enter specific bacteria to disrupt the barrier function. 
There is an ongoing dispute on the origin and physiological function of antibiotic substances when 
created naturally by microbes (Kumbhar & Watve, 2013). Some antibiotic substances develop to have 
a signalling role, such as alternating morphogens for streptomycetes, when the bacteria lack nutrition, 
the life cycle ends up changing including the function of the antibiotic (Aminov, 2010; Domínguez & 
Meza-Rodriguez, 2019). 
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Antibiotics have different molecular ways to eliminate bacteria, for example, inhibiting growth, 
protein synthesis, nucleic acid synthesis, cell wall synthesis, enzyme activity, specific biochemical 
processes and altering cell membrane permeability (Kapoor, Saigal & Elongavan, 2017). Some 
examples are briefly explained in Table 1. Traditionally, antibiotics have been classified as 
bacteriostats which stop cell growth or bactericides that kill bacteria. Bacteriostats rely mostly on the 
host immune system to eliminate the bacterial infection. However, bacteriostatic antibiotics can 
become bactericidal when used at a high concentration, hence, this method of classification is not 
enough (Kapoor, Saigal & Elongavan, 2017). Another more recent method to classify antibiotics is to 
observe antibiotic activity, if it is reliant on time, concentration or is it co-dependent (Table 1). 
Information on how the antibiotic operates is important, however, more data is required on the 
spectrum of activity (which microbes are susceptible to the antibiotics), level of resistance detected 
(due to repetitive use) and if the concentrated antibiotic is effective in vivo with therapeutic dose rates 
(Kapoor, Saigal & Elongavan, 2017). 
Pharmacokinetics and pharmacodynamics can explain the antibiotic’s subsequent effects and 
association between the dose and body response (Campbell & Cohall, 2017). The pharmacological 
reaction mainly relies on the antibiotic binding to its target. The antibiotic concentration at the 
receptor site has a great impact on the effectiveness of the drug (Campbell & Cohall, 2017). The 
pharmacodynamics of the antibiotic can be influenced by physiological alterations caused by genetic 
mutations, aging, disease and other antibiotics. A physiological change may transpire due to the 
capability of disorders to modify receptor binding, alter the amount of binding proteins, or reduce the 
sensitivity to receptors (Campbell & Cohall, 2017).  
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1.17				Antibiotic	resistance		
At present, there is a universal concern for the era of antibiotics as it is coming to an end (Santiago & 
Maximino, 2016). It is predicted that medicine in the near future may return to 19th century medicine 
where one slight injury may cause deadly infection and death (WHO, 2014). For decades antibiotics 
have been used globally and repeatedly. Since 1935, all infections caused by bacteria have been cured 
quickly, even if the last generation of bacteria showed resistance to antibiotics (Aminov, 2010; 
Domínguez & Meza-Rodriguez, 2019). Resistance to antibiotics is inevitable. All animals including 
humans live with a large variety of bacteria in their gut and skin microflora, most of these microbes 
namely commensals are highly valuable or completely innocuous (Conlan et al., 2012). Only a small 
portion of these commensals are capable of becoming harmful based on what niche they live in or 
what area of the host they occupy (Conlan et al., 2012). 
The discovery of antibiotics was and still is a breakthrough in treating bacterial infection, however, 
due to the overuse of antibiotics there are now antibiotic-resistant strains of pathogenic microbes 
(Aminov, 2010; Domínguez & Meza-Rodriguez, 2019). This method of treatment lead to non-reversible 
mutation in new resistant strains of pathogens or commensal bacteria (Conlan et al., 2012; Santiago 
& Maximino, 2016). This is a global health problem which requires an urgent solution as it may lead 
to a permanent unbalance skin and gut microflora. This is why there are laws and regulations put in 
place to limit the use of antibiotics for minor infections (Dreno et al., 2016).    
The world population of bacteria is approximately 5 x10$%, this means every individual on this planet 
has around 50 tons of bacteria (Namkeleja et al., 2016). Bacteria has the capacity to replicate their 
DNA and divide rapidly, also, if the bacteria have specific nutrients available to it, it is capable 
of duplicating every twenty minutes within the gastrointestinal tract (Pfeifer et al., 2019). The DNA 
transcriptase in a given bacteria make around one mistake in every 10⁶ base pairs of replicated DNA 
(Namkeleja et al., 2016). If 3 to 10 mutations occurred within a bacterial genome for every generation, 
the bacterial populace of 10⁸ in a particular niche would most likely have 300 to 1000 variants. There 
is a high possibility of one of these mutations to cause resistance to the mode of action of an antibiotic, 
such as penicillin. When the bacteria are exposed to a strong concentration of antibiotic with sufficient 
amount to kill the bacteria, the sensitive bacteria will perish. The resistant duplicate bacteria that was 
once an exceptionally minor mutant in the microbial community, has now access to nutrients and 
space released by the dying neighbouring bacteria, the resistant duplicate microbe will gradually 
become widespread in the community. It has been calculated that, when obtained as a group, the sum 
genes for bacteria found in the soil worldwide go through four separate mutations every 3.4 hours. 
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Substantial number of mutants are bound to exist in the estimated world population of bacteria (5 
x10$%) (Namkeleja et al., 2016). 
Strong and speedy antibiotic prescriptions work remarkably well when the bacterial population is 
destroyed completely (Aminov, 2010; Domínguez & Meza-Rodriguez, 2019). However, when this does 
not occur, the outcome of antibiotic usage becomes disadvantageous. As S. epidermidis is a part of 
the normal microbiota for healthy humans, it has developed resistance to numerous antibiotics that 
are used frequently, for example, methicillin, novobiocin, clindamycin, and benzyl penicillin (Saffari et 
al., 2016). Consequently, other antibiotics namely vancomycin or rifampin are now used to treat 
infections.   
S. epidermidis contain integrated plasmids that carry genes encoding species-specific LPXTG surface 
proteins and resistance to cadmium. S. epidermidis Genome Island may encode possible virulence 
factors including numerous phenol-soluble modulins (Xue et al., 2017). S. epidermidis contain cap 
operon (capABC) and gamma-glutamyl transpeptidase gene as found on the B. anthracis pX02 
plasmid, which encodes polyglutamate capsule, a key virulence factor of Bacillus anthracis (Xue et al., 
2017). Any other phenotypic variances are possibly caused by single nucleotide polymorphisms which 
can be seen in most cell envelope proteins. Phylogenetic study of cap genes in the operon specify that 
the attainment of this locus may be created by a plasmid-mediated transfer event from the ancestor 
of bacilli to S. epidermidis. Nevertheless, several species-specific metabolic functions including 
polyphosphate synthesis and acetoin dehydrogenase are encoded by complete operons in S. 
epidermidis, this may be due to gene loss by a common ancestor (Xue et al., 2017). 
Five key mechanisms have been identified to cause antibiotic resistance, including, the formation of 
deactivating enzymes, alteration in target sites, initiation of alternative pathway e.g. bypass pathway, 
the inability to activate antibiotics and antibiotic prohibition from active efflux of target site 
(MacGowan & Macnaughton, 2017). The main mechanism that cause antibiotic resistance is the 
chemically modified antibiotic molecule as well as the destroyed antibiotic molecule. Secondly, 
mutated target sites, altered enzymatic function of the target sites and full substitution or bypass of 
target sites cause the most antibiotic resistance. Furthermore, majority of antibiotic resistance occur 
when there is low porosity and deceased amount of efflux pumps. (Munita & Arias, 2016).  
The consecutive attainment of resistance in most classes of antimicrobial agents, including 
tetracycline, macrolides, aminoglycosides, penicillin and chloramphenicol, has made curing and 
controlling S. epidermidis infections increasingly problematic. 
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During the late 1960s, semisynthetic penicillin and methicillin were extensively used and led to the 
rise of methicillin-resistant S. aureus (MRSA) and S. epidermidis (MRSE), which persists today in both 
community environments and health care settings (Stamatiou et al., 2013). S. epidermidis are known 
to contain specific antibiotic resistant genes, especially for methicillin, which is one of the first 
antibiotic used to treat S. epidermidis infections, approximately 75–90% of S. epidermidis isolates 
found in a hospital setting had methicillin resistant gene, oppose to S. aureus isolates with only 40–
60% harbouring methicillin resistant gene (Stamatiou et al., 2013). S. epidermidis carry mobile genetic 
elements (MGEs) called Staphylococcal cassette chromosome mec (SCCmec) comprising of mecA gene 
which encode a penicillin-binding protein (PBP) with low methicillin affinity (Rolo et al., 2012; Mirzaei 
et al., 2017). PSM-mec (20–25 amino acids), a short α-type PSM is also encoded by SCCmec (Cheung 
et al., 2014). PSM-mec has the ability to activate and stimulate neutrophils (Qin et al., 2016) via human 
formyl peptide receptor 2 (FPR2) interaction, the G protein-coupled receptor is expressed on different 
types of host immune cells. PSM-mec can immediately up-regulate the expression of both CD11b and 
gp91phox, induce calcium flux, chemotaxis, and IL-8 release in neutrophils (Qin et al., 2016). Not only 
does S. epidermidis mecA gene encode for methicillin resistance but also broad β-lactam resistance 
(Saffari et al., 2016). 
In addition to this, ten various SCCmec elements have been found in S. epidermidis. The most 
commonly identified SCCmec element in S. epidermidis is the small SCCmec type IV structure which 
may spread without damaging the fitness of its host bacteria and evade specific antibiotic pressures 
(Xue et al., 2017). Moreover, Staphylococcal variants carry various type of SCCmec structures and S. 
epidermidis frequently uptakes and emits SCCmec elements. 
Furthermore, S. epidermidis is resistant to lots of other antibiotics besides methicillin such as 
erythromycin chloramphenicol, gentamicin, flouroquinolones, rifamycin, sulfonamides, tetracycline 
and clindamycin (Saffari et al., 2016). Also, S. epidermidis is less likely to be resistant to tigecycline, 
streptogramins, and linezolid and is found to be intermediate resistant to vancomycin. The capability 
of S. epidermidis to form biofilm greatly reduces the likelihood of vancomycin and other antibiotics to 
have an effect (Saffari et al., 2016). Bacteria plasmids mostly encode antibiotic resistant genes and are 
frequently found in methicillin-resistant instead of methicillin-susceptible variants. Endemic 
nosocomial strains of S. epidermidis are usually resistant to both methicillin and other antibiotics 
(Stamatiou et al., 2013). 
The overuse of antibiotic treatment for S. epidermidis infection reflect the high-level of antibiotic 
resistance within S. epidermidis. The ubiquity of S. epidermidis as a symbiotic microbe on the human 
skin, makes it an ideal reservoir for antibiotic resistant genes especially the SCCmec elements that do 
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not incur a fitness cost to the host (Xue et al., 2017). Thus, several lines of evidence suggest that S. 
epidermidis cassette chromosome mec which encode methicillin resistance are transmitted to S. 
aureus (Gill et al., 2005). Also, the uptake of SCCmec type IV by community associated methicillin-
resistant S. aureus (CA-MRSA) has largely influenced public health (Xue et al., 2017). CA- MRSA is a 
name given for an infected person who has not visited a healthcare facility such as a dialysis centre, 
nursing home or a hospital. SCCmec type IV has allowed the bacteria to remain fit to spread highly 
virulence toxins while being resistant to methicillin, hence, causing the epidemiology of CA-MRSA 
strains (De Leo et al., 2010). Furthermore, recent evidence suggests that MGEs can be transferred via 
horizontal gene transfer from S. epidermidis to CA-MRSA, which is vital for the spread of disease. 
Consequently, CA-MRSA infections mainly rely on S. epidermidis acting as a reservoir for genetic 
factors which are then transferred to S. aureus, making it important for CA-MRSA to colonise 
successfully (De Leo et al., 2010). 
Although S. epidermidis does not carry a large variety of virulence factors, S. epidermidis is highly 
resistant to several antibiotics. In a study carried out by Mendes et al. (2012), 50% of S. epidermidis 
strains were found to be resistant to different kinds of antibiotics. Moreover, 70% of S. epidermidis 
isolates from a hospital setting was found to be resistant to Oxacillin (Mendes et al., 2012; Flamm et 
al., 2013). In a study done by Sahal & Bilkay (2014), all S. epidermidis strains were sensitive to 
vancomycin, yet 65% of them exhibited resistance to all β-lactam antibiotics including Penicillin, 
Oxacillin and Amoxicilin/Clavulonic acid, 60% of all S. epidermidis strains were found to be multi 
antibiotic resistant (Sahal & Bilkay, 2014).  
Staphylococcus species have the capacity to adapt quickly and become resistant to one or several 
other antibiotics. Only 10% of current Staphylococcal infections can be treated with penicillin. To cure 
Staphylococcal infections and combat antibiotic resistance, it is important to test for new treatments 
and interventions. Also, it is vital to research new means for prevention, detection, treatment and to 
manage Staphylococcal infections (Xue et al., 2017). The effectiveness of vancomycin is limited due to 
the rise of vancomycin-intermediate S. aureus and more recently vancomycin-resistant S. aureus. The 
collective occurrences of hypervirulence community-acquired S. aureus have become a global concern 
to the health community and is in a serious need for new methods of control and treatment (Xue et 
al., 2017). 
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1.18	 The	importance	of	antibiotic	research							
One possible way to control the rise of microbial resistance is to develop new effective antimicrobial 
agents instead of unsuccessful drugs (Saxena et al., 2019). Thus, it is important on an international 
level to research new antibiotic of enhanced activity or unique structure from the limitless source of 
microbes as resistant bacteria continue to surge. AMR is identified as one of the main threats of the 
21st century to global health, food security and development. Antibiotics can be bought over the 
counter without prescription for human or animal usage, the appearance and widespread of 
resistance is worsened. Likewise, in countries with no normal treatment guidelines, antibiotics are 
usually over-prescribed by health employees and over-used by the populace.  AMR have repetitively 
emphasised the vital need for action by national and international organisations (O'Neill, 2014; Davies 
& Gibbens, 2013).  
The second leading cause of global death are infectious diseases, regardless of the advancement made 
in the identification and development of antibiotics (Silber et al., 2016). Infections caused by multi-
drug resistant variants show major clinical sign of drug resistance leading to a progressive interest in 
the research of AMR. Advance screening programs are vital for the selection of various natural and 
altered chemical compounds to determine new antibiotics active against resistant bacteria (Sanchez 
et al., 2010). Furthermore, there is a growing requirement of antibiotics worldwide. For instance, 
“marketresearch.com” study highlighted China’s need for penicillin which grew exponentially from 
1990 to 2000, this trend was predicted to grow and spread over the following years (Dayalan et al., 
2011). 
Several processes of antibiotic resistance commonly develop a fitness cost, which is a significant 
biological limitation that positively impact progression of resistance. Mutations that confer small 
amount or no fitness cost are highly likely to survive and grow without antibiotic therapy (Melnyk et 
al., 2015). At the community level, the fitness cost caused by resistance is reversible. However, 
community-level reversibility rate is slow due to compensatory evolution, co-selection of resistance 
genes and costless mutations. Furthermore, the larger the fitness cost, the quicker the reversibility 
(Melnyk et al., 2015). 
Information about fitness costs and compensatory mutations can be utilised to decrease the 
possibility of bacteria becoming resistant. This can enable researchers to select antibiotics with 
resistance mechanisms that have huge fitness costs along with low frequency compensation 
mutations. Thereby exploiting the in-depth information on physiological aspects of fitness costs, it is 
possible to select specific novel therapy designs that focus on physiological weak points connected to 
specific resistance mechanisms (Melnyk et al., 2015).  
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Current research studies emphasise the significance of gathering large amounts of data based on 
epidemiology of antibiotic resistance (Frieri et al., 2016). This is important as it will help in constructing 
new control programmes for the evolving universal health crisis, namely, antibiotic resistance. 
Nosocomial microbial plasmids need to be isolated for molecular characterisation to produce 
invaluable data to aid in developing novel control strategies for clinical infectious microbes. 
1.19	 Adaptive	resistance	(AdR)	 	
Antibiotics provide key defence mechanism against various infectious pathogens that cause disease. 
Due to this, antibiotics have increasingly been produced and distributed significantly over the last 
seven decades. This has resulted in the careless overproduction of antibiotics not only for treatment, 
but largely as food additives for plants, poultry and cattle. The non-selective overuse of antibiotics has 
led to drastic microbial adaptation, where the microbes have established systems to avoid antibiotic 
eradicating them.  
From the time antibiotics were introduced as antibacterial medium, the starting point of minimum 
inhibitory concentration (MIC) for several antibiotics has increased dramatically over the years. One 
example of this ‘MIC creep’ is erythromycin having a 250-fold MIC upsurge in the last five years. 
Another example of an antibiotic demonstrating a rise in MIC is ciprofloxacin with a 120-fold MIC 
increase in nineteen years. However, a combination of events may have caused the mentioned MIC 
upsurge, nonetheless, the large quantity of construction and distribution of antibiotics has 
undoubtedly led to the increased MIC. 
Microbial communities can become resistant to antibiotics via three known mechanisms; intrinsic, 
acquired and adaptive resistance (Jose et al., 2016). Intrinsic resistance involves all the innate 
processes of certain microbes that may inhibit the influence of antibacterial agents, for example, efflux 
pumps and cell membrane restrain antibiotics from influencing the microbe. Secondly, acquired 
resistance involves the integration of deoxyribonucelic acid (DNA), possibly through exchange of 
plasmid genetic material or mutation within the microbe that may develop new capacities to resist 
strong concentration of antibiotic (Jose et al., 2016). Lastly, adaptive resistance (AdR) requires 
a universally accepted definition, while Hancock and Férnandez (2012) defined AdR as a brief rise in 
the capability of a microorganism to resist an antibiotic attack due to gene variations and/or protein 
expression trigged by the environment.   This specific mechanism of antibiotic resistance, oppose to 
intrinsic or acquired, is reliant on the existence of antibiotics. The AdR requires communication with 
antibiotics to trigger resistance or fixate the resistant phenotype. However, during certain events AdR 
may function as a link between the acquired and intrinsic resistance, as heritable mutations or 
  
39 
 
epigenetic alterations, induced by environmental indicators, may change the expression of innate 
defence system in turn elevating the microbial resistance to antibiotics (Jose et al., 2016). 
The procedure to produce AdR is to firstly expose the microbial community to small doses of antibiotic 
and then slowly raise the level of concentration. This can be attained by initially exposing the microbial 
populace to harmless concentrations of antibiotics, thereby activating the innate defence system and 
preparing the microbial community to survive stronger doses of antibiotics. 
One particular feature of AdR is the variation shown in the phenotype of microbes within a populace, 
this is also identified in closely similar or identical genotypic microbial colonies (Jose et al., 2016). 
Although the microorganisms share the same genotype, some of them are capable of surviving 
whereas others die. The isogenic colonies share same ancestors and are exposed to the same 
surroundings, yet some of the microbes show changes in the phenotype and become resistant. The 
phenotype alterations can be due to different trends of gene expression. Furthermore, around 20% 
of microorganisms have the capacity to survive at subinhibitory level of concentration, this indicates 
that phenotypic variations within a microbial community is not caused by gene mutations. If the 
phenotypic variations were due to genetic modifications, the expected survival rate would be a lot 
higher than 20%. The phenotype that displays bacterial resistance has low level of stability and cannot 
be found in some generations of bacteria when grown without antibiotics. This also indicates that AdR 
is not due to genetic alterations as that would commonly produce irreversible phenotypes (Jose et al., 
2016).  Moreover, the resistant phenotype may be due to epigenetic modifications as this is known to 
be very unstable. The microbial populace displays a gradual increase in resistance and only few of the 
microbes eventually become resistant, not all of them. This suggests that few microbes must inherit 
some memory of the process that causes phenotypic resistance.  
Although, there has been a lot of progression in the development of antibiotics and in the treatment 
of bacterial infections, no permanent solution has been found for the complication of bacteria 
becoming resistant to several antibiotics. Out of all known forms of resistance, AdR is the most 
problematic as this phenotype is produced by concentration gradients and when in contact with 
subinhibitory concentration of antibiotics. Both of these mechanisms occur within human and farm 
animals. Likewise, AdR has been associated with the emergence of various antibiotic resistance, 
despite there being little understanding of why it occurs and the biological process of AdR (Jose et al., 
2016).  Some research studies have suggested that epigenetic inheritance, high level of mutations, 
efflux pumps, gene amplification, structure and phenotypic variations within a population and the 
production of biofilm may have contributed to the emergence of AdR. Nevertheless, when these 
notions were researched separately, the researchers failed to stop the quick emergence of AdR or 
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anticipate the high levels of instability (Jose et al., 2016). Variants of resistant bacteria keep on 
emerging while the current methods to kill them such as, efflux inhibitors, sequential treatments and 
combined antibiotics are proving to be highly ineffective (Pizzolato-Cezar et al., 2019). 
In a recent study, researchers analysed a collection of global S. epidermidis strains (Popescu, 2018). 
They found that 74% of the isolates from hospital-associated infections belonged to a distinct S. 
epidermidis clonal complex. These isolates were from three separate lineages, most of them were 
nosocomial with substantially enhanced antibiotic resistance and biofilm formation capacity, thus, 
signifying (hospital) adaptation resistance. The three S. epidermidis lineages share a rpoB mutation 
which cause resistance to rifampicin (Popescu, 2018). In addition to this, researchers identified a 
21.7% increase (2007 - 2013) in teicoplanin-resistant S. epidermidis strains in an Australian 800-bed 
hospital (Popescu, 2018). 
Present information on AdR suggest that it is frequently mediated by fitness costs, biological gain-of-
function and physiological adaptations. Genetic mutations and phenotypic adaptation can alter 
bacterial metabolism causing an impaired biological efficiency. To manage adaptive resistant S. 
epidermidis strains, a possible yet an unexplored method can be used to categorise and inhibit 
metabolic pathways that are important for AdR (Zhong et al., 2018). The metabolome commonly 
refers to the whole set of low-molecular weight molecules (metabolites). Metabolomic analysis is a 
measurement of metabolites to evaluate the metabolomic processes that are required for the 
maintenance of growth and normal function of a cell in a specific physiological or developmental stage 
(Xu et al., 2018). Metabolic profiling is a vital aspect as well as proteomics, transcriptomics and 
genetics data, to allow a comprehensive representation of the interactions between proteins, 
transcripts, metabolites and genes in microbes (Xu et al., 2018). Therefore, MSE was used in this 
research study to observe and analyse any differences in metabolome before and after antibiotic 
adaptation. 
MSE is a technique used by Water informatics to acquire accurate data with the strength of mass 
spectrometry and UltraPerformance LC (Waters, 2011). MSE only requires one experiment for exact-
mass precursor, fragment ion data, sample identification and quantification.  Mass spectrometry 
technique has high sensitivity with an improved in-spectrum dynamic range to detect components, 
irrespective of the concentration, accurate mass and isotopic pattern is digitally recorded (Waters, 
2011). UltraPerformance LC has the capacity to demonstrate advance levels of chromatographic 
separation and rapidly generate constricted chromatographic peaks. MSE is easy to set up, does not 
need a lot of parameters to be adjusted and little method alteration for application with no previous 
research on the sample components (Waters, 2011).  
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Microbial fitness and virulence are affected by AdR and genetic systems e.g. genetic co-selection and 
compensatory mutations (Beceiro et al., 2013). Some resistance mutations may experience no fitness 
costs and persist in the populace without the pressure of antibiotic selection. On the other hand, costs 
of resistance can be balanced out through second-site mutations which re-establish microbial fitness 
with no antibiotic exposure (Beceiro et al., 2013). The relationship between virulence and resistance 
reflects the Darwinian model, where specific advantageous traits are selected at some point in time 
and become permanent. A positive correlation between resistance and virulence can infer a speedy 
selection of advantageous traits (Beceiro et al., 2013). A negative correlation between resistance and 
virulence (high resistance and low virulence) causes a longer selection period for the specific virulent 
factors to become permanent in the populace (Melnyk et al., 2012). In contrast to this, there can be 
an increase in virulence with a decrease in resistance. This is where compensatory mutations may 
occur to produce a positive correlation between resistance and virulence, hence, allowing the bacteria 
to have a permanent selective advantage. Research on bacterial virulence require an appropriate 
animal model, for example, insects, as they have a similar mammalian innate immune system (Melnyk 
et al., 2012). Hence, G. mellonella virulence assay was used in this study to observe differences 
between pathogenicity in parent strains and antibiotic adapted strains.  
A wax worm that is also known as a caterpillar larva belong to the G. mellonella species, from the 
Order named Lepidoptera and the Pyralidae Family (Tsai et al., 2016). The average length of wax 
worms is 2-2.5 cm and are cream in colour (Figure 3A).  The insect G. mellonella and mammals share 
similar functioning phagasomes, for example, sugranulocytes and plasmatocytes (Tsai et al., 2016). 
Additionally, G. mellonella wax worms produce neutrophils which express distinct proteins that are 
almost identical to human calreticulins, these proteins usually play a role in non-self-recognition for 
defence responses induced by cells. G. mellonella can be used as an effective virulence model to study 
pathogenic microbes. G. mellonella is the most suitable model to use when researching bacterial 
infections opposed to other model hosts as researchers do not require ethical authorisation, and the 
wax worm model is economical due to low-cost while easily sustained with a decreased life span 
(Melnyk et al., 2012). Furthermore, when G. mellonella wax worms are differentiated against their 
invertebrate equivalents such as Drosophila melanogaster and Caenorhabditis elegans, they are able 
to survive 37 °C temperature (ideal temperature for most microorganisms to grow), allowing G. 
mellonella to be the most optimum virulence model for bacterial infection research (Tsai et al., 2016).  
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Figure 9. Photographic images of G. mellonella. (A). Image of a healthy G. mellonella larvae. (B). 
Images of an infected larvae at different stages of disease. Melanisation, which involves the 
production and deposition of melanin to encapsulate microbial pathogens at the inoculation 
spot accompanied by haemolymph coagulation with characteristic black spots on the larvae. 
Complete melanisation associated with death of the larvae thereafter.  In addition, a reduction 
in cocoon formation is an indicative marker for disease in G. mellonella larvae. The numbers 
represent the assigned health index scores based on the G. mellonella Health Index Scoring 
System (Tsai et al., 2016).  
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1.20					Unidirectional	horizontal	gene	transfer		
S. epidermidis frequently transfer mobile genetic elements to S. aureus, excluding toxin genes, still it 
may be possible for S. epidermidis to uptake toxin genes from S. aureus through a similar process 
(Common et al., 2019). Recent studies of clustered regularly interspaced short palindromic repeat 
sequences (CRISPR) demonstrate short repeats that may stop S. epidermidis from acquiring 
conjugative plasmids and phage from other bacteria (Szemraj et al., 2019). This may explain why the 
transmission of mobile genetic elements between S. epidermidis and S. aureus is unidirectional 
(Águila-Arcos et al., 2017). Clustered regularly interspaced short palindromic repeat sequences are 
not found in S. aureus genomes but have been detected in S. epidermidis strains. The role of S. 
epidermidis CRISPR sequence requires a better understanding and further research on how it prevents 
the uptake of mobile genetic elements (Common et al., 2019). This mechanism may signify why S. 
epidermidis lack a large variety of toxins and are avirulent (Águila-Arcos et al., 2017). 
A bacterium can obtain a resistant gene via horizontal gene transfer. Plasmid containing tra genes are 
transferred to other bacteria through a complicated process of conjugation, this is known to be the 
main cause of new resistant pathogens (Schiwon et al., 2013; Águila-Arcos et al., 2017). Bacteria can 
directly transfer genetic material to other cells in a biofilm as the biofilm supplies a perfect place to 
switch genes originated from several microbes. Nonetheless, microbial conjugation may encourage 
biofilm production as microbial cells need to be present close to each other in order to exchange 
resistance genes (Donne et al., 2015). The relationship that bacterial conjugation and biofilm share 
raises the possibility of biofilm infections to disseminate virulence agents. 
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Aim	of	the	study	 
The main aim of this study was to characterise bacteria isolated from human skin before and after 
exposure to antibiotics in terms of their antibiotic susceptibility, biofilm formation, and virulence. To 
find and emphasise the important role of S. epidermidis in human disease by functioning as a reservoir 
for virulence genes and the possible pathogenic role it may play to cause disease. This will further 
provide insights in understanding the manner S. epidermidis -associated bacteria can adapt, as well as 
the likely consequences for diagnosis and treatment.  
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CHAPTER	2	
	
MATERIALS	AND	METHODS	
2.1	 Selection	of	parent	strains	
Five isolates of Staphylococcus epidermidis (SE1, SE2, SE3, SE4 and SE5) were obtained from human 
skin and sub-cultured onto Müller-Hinton Broth (MHB, Oxoid Limited, UK) and Müller-Hinton Agar 
(MHA, ProLabo, India), and incubated at 37 °C for 24 h (EUCAST, 2019). 
 
2.2	 Antibiotic	susceptibility	testing	(disc	diffusion	assay)		
The susceptibility of both parent and antibiotic-adapted strains were determined before and after 
adaptation to antibiotics according to the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST, 2019) guidelines using disc diffusion method. Suspensions of the organisms were prepared 
in Phosphate Buffer Saline (PBS), compared to a 0.5 McFarland turbidity standard, and spread on MHA. 
Thereafter, commercially obtained antibiotic discs (Oxoid, United Kingdom) were applied and 
incubated at 35±1 °C for 24 h according to EUCAST (2019) guidelines. Antibiotics used include: 
doxycycline (30 µg), ciprofloxacin (5 µg), erythromycin (15 µg), cefalexin (30 µg), amoxicillin (25 µg), 
trimethoprim (5 µg), clarithromycin (15 µg), linezolid (10 µg), metronidazole (5 µg), azithromycin (15 
µg) and co-amoxiclav (30 µg). The entire procedure from preparation of suspension containing the 
inoculum, the application of the antibiotic discs, and the incubation of plates were all completed 
within 15 minutes’ interval adhering to the 15-15-15-minute rule according to EUCAST (2019). This 
was followed by the assessment of bacterial growth against antibiotics (antibiogram pattern) by 
measuring the zones of inhibition and documenting the results using EUCAST Clinical Breakpoint 
Tables (EUCAST, 2019).  
 
2.3	 Selection	of	antibiotic-adapted	isolates	
Weekly serial passage exposure experiments were set up using antibiotics that were effective against 
parent strains through aseptic selection of growth closest to the terminal point of the zones of 
inhibition, and used to inoculate a subsequent plate, antibiotic was added and incubated for 48 h at 
37 °C (a single passage). After each passage, a separate streak was made to ensure culture purity. This 
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procedure was repeated for 9 passages and zones of inhibition were measured at every passage. 
Thereafter, frozen stock of the parent strains (designated P0) and antibiotic-adapted strains (P9) were 
stored at -80 °C for further analysis.  
 
2.4		Determination	of	cross-resistance	
After 9 passages, the antibiotic-adapted strains of S. epidermidis were spread on MHA and antibiotic 
discs applied and incubated at 37 °C. Individual zones of inhibition were measured and compared with 
the 9th passaged antibiotic-adapted strains to access cross resistance (EUCAST, 2019). 
 
2.5	Determination	of	biofilm	formation		
Biofilm formation was analysed using the crystal violet biofilm assay (O'Toole, 2011).  Overnight 
suspensions of susceptible parent strains and antibiotic-adapted strains of S. epidermidis were diluted 
1 in 100 in MHB, and 100 µl aliquots of each were transferred to a 96-well plate (4-6 replicate wells 
per treatment) alongside negative controls (MHB). Plates were incubated aerobically at 37 °C for 24 h 
enclosed within a humidified vessel to reduce evaporation. Optical density (OD) of planktonic bacteria 
was measured and contents discarded, followed by addition of 125 µl of 1% (wt/vol) crystal violet stain 
to corresponding wells and incubated at room temperature for 10 minutes. This was removed, and 
the wells were washed thrice with distilled water and the plates were left to air dry. Thereafter, 
biofilm-attached crystal violet was extracted with 250 µl ethanol following incubation at room 
temperature for 10 min, and the absorbance was read using a microplate reader (FLUOstar Omega, 
BMG LABTECH) at 600 nm. The results obtained were expressed as the mean of biofilm-attached 
crystal violet absorbance comparative to the absorbance rates subtracted from the negative controls. 
Relative biofilm-forming units were calculated by dividing the absorbance of biofilm-attached crystal 
violet by the equivalent planktonic OD. The entire assays were performed in triplicate. 
 
2.6				Determination	of	relative	fitness						
Overnight cultures of S. epidermidis parent strain (P0) or antibiotic-adapted strain (P9) were diluted 
1:10 with the OD of 0.1 at 600 nm. Sterile TSB with 1% glucose (10 ml) was inoculated in triplicate with 
P0 or P9, alone or in combination. Flasks were incubated at 37 °C shaking at 100 rpm for 24 h. At 24 
h, dilutions from each flask were plated onto MHA in triplicate and incubated at 37 °C for 18 h. 
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Bacterial viable counts were determined after 18 h of incubation, and relative fitness was assessed for 
bacteria grown independently and in combination, using the equation W = In (RF/RI) / In (SF/SI), where 
the W refers to relative fitness, RI and SI refer to the numbers of P9 and P0 cells at the start point, 
respectively, and RF and SF refer to the numbers of P9 and P0 cells at the endpoint (Latimer et al., 
2012).                             
 
2.7	 Waxworm	infection	assay	
Microbial virulence of susceptible parent strains and antibiotic-adapted strains (2 per organism) were 
determined using the Galleria mellonella (waxworm) infection assay (Brignoli et al., 2019; Latimer et 
al., 2012; Tsai et al., 2016). Final larval-stages of G. mellonella (Livefoods Direct, UK) were kept in the 
dark at 4 °C for < 7 days, and 18 were randomly allocated to each respective category and incubated 
at 37 °C for 30 min. Thereafter, overnight suspensions of susceptible parent strains and selected 
antibiotic-adapted strains were washed twice in PBS and diluted suitably in PBS to attain an OD of 0.1 
(5 x 105 - 8 x 105 CFU/ml) at 600 nm. 5 µl of each suspension was inoculated into the hemocele of each 
larva via the eight left pro-leg with aid of a Hamilton syringe (2.5 x 103 - 4 x 103 CFU per individual). 
Larvae were incubated in plastic petri dishes at 37 °C, and the number of surviving larvae was 
documented day-to-day (lifeless larvae were insensitive to touch and appeared dark in colour). A non-
treated category and PBS inoculated category were used as negative controls. The experiments were 
discontinued once the death of a minimum of 2 individuals in a control category was observed. The 
experiments were performed once for both parent strains and antibiotic-adapted strains. 
 
2.8   Metabolite extraction	for	MSE 
The process of metabolite extraction from suspended microbial cells involve quenching (by addition 
of organic solvent followed by extraction of internal metabolites into the extraction solution. The 
subinhibitory concentration (colonies from the inner circumference of zone of inhibition) as well as 
zero-inhibitor concentration (colonies from the side of the agar plate) of samples SE1, SE2, SE3 
adapted to Amoxicillin, Doxycycline Hydrochloride and Ciprofloxacin were taken using a sterile loop 
and inoculated into 10 mL of 60% methanol (-48 °C) (in 5, 10 and 20 mL). The samples were centrifuged 
at 4300 g for 10 min at -8 °C to pellet cellular mass. The cell media was removed and re-centrifuged at 
4300 g for 10 min at -8 °C, the residual quenching media was removed again. Extraction can be 
performed immediately or stored at -80 °C. The TissueLyser adapter set (2 x 24) was stored at -80 °C 
for 2 h prior to starting disruption and homogenisation, the Eppendorf tubes containing the samples 
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were pre-cooled on dry ice. Each sample was transferred to 2 mL micrcentrifuge tubes containing 25-
50 mg (pretreated nitric acid- washed) glass beads (150-600 µm mean diameter). The TissueLyser was 
operated for 5 min at 30 Hz. The duration of disruption and homogenisation was extended until no 
debris was visible. The biomass pellets were suspended in 1 mL of 80% methanol (-48 °C). The 
dissolved pellets were transferred to  chilled 2 mL Eppendorf tubes, flash-frozen in liquid N₂ for 1 min 
then allowed to melt on wet ice. Upon thawing, the tubes were vortexed for 30 s.  The samples were 
flash-frozen and vortexed two more times. The samples were centrifuged at -9 °C, 14,500 g for 5 min, 
supernatant was then transferred into fresh 2 mL Eppendorfs. 500 μL of extraction solvent was added 
to the biomass pellets, to be suspended in 1 mL of 80% methanol (-48 °C). The dissolved pellets were 
transferred to chilled 2 mL Eppendorf tubes to be flash-frozen in liquid N₂ for 1 min, melted on wet 
ice and vortexed for 30 s three times. The extracted solution was added to the same final 2 mL 
Eppendorf. 2 μL of each sample was trasferred into one Eppendorf tube to produce a QC sample. The 
Eppendorf tubes containing the extracts were left to dry out in the Eppendorf Vacufuge. Solid pellets 
were immediately stored at -80 °C. The Eppendorf tubes containing samples metabolite extracts were 
transported on dry ice and securely packaged to Waters for mass spectrometry metabolome analysis 
(Goodacre et al., 2005). 
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2.9	 Statistical	analysis	
Data obtained were analysed using Minitab 17 software and Microsoft Excel 2017. Graphical 
representations showing antibiotic susceptibility patterns, biofilm formation was plotted using 
Microsoft Excel 2017, while survival data were plotted using the Kaplan–Meier method (Prism v 7.03). 
Results were statistically presented as mean ± standard deviation (SD). Differences of p < 0.05 were 
considered statistically significant via One tailed T-test method. 
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Chapter	3			
3.0	Results	
3.1	Antibiotic	susceptibility	pattern	
The antibiotic susceptibility patterns of parent strains used in this study was interpreted using EUCAST 
Breakpoint Table. As indicated by their zone diameters, parent strains of S. epidermidis was sensitive 
to the following antibiotics: doxycycline, ciprofloxacin, erythromycin, cefalexin, amoxicillin, 
trimethoprim, clarithromycin, linezolid, azithromycin and co-amoxiclav (Table 2-6). Furthermore, it is 
observed that the 9th passage (P9), antibiotic-adapted strains of S. epidermidis remained sensitive to 
cefalexin, amoxicillin, trimethoprim, clarithromycin, linezolid, azithromycin and co-amoxiclav, 
however, it was resistant to doxycycline, ciprofloxacin and erythromycin (Table 2, 3 and 4).  
 
Table 2. Antibiotic susceptibility pattern of Doxycycline adapted strain with zone diameters (sample: 
SE1-SE5) 
 
 
 
 
 
 
  
 
 
 
 
 
 
SE1                                                                    Zone diameter (mm) 
Antibiotic Disc content (µg) Parent strain 
  
Doxycycline -
adapted  
 strain  
 S                 R   S                  R  
Doxycycline 30 15                                       4 
Ciprofloxacin 5 27                                     13 
Erythromycin 15 22                                       0 
Cefalexin 30 35                  33                     
Amoxicillin 25 31                 29                  
Trimethoprim 5 25 27 
Clarithromycin 15 34 40 
Linezolid 10 36 33 
Metronidazole 5                   0                     0 
Azithromycin 15 24 21 
Co-amoxiclav 30 35 39 
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SE2                                                             Zone diameter (mm) 
 Antibiotic Disc content (µg) Parent strain  Doxycycline -
adapted strain   
 S              R   S                 R  
Doxycycline 30 18                                      8 
Ciprofloxacin 5 26                                    12 
Erythromycin 15 24                                      0 
Cefalexin 30 32                  30                      
Amoxicillin 25 30                 27                  
Trimethoprim 5 28 25 
Clarithromycin 15 32 25 
Linezolid 10 35 30 
Metronidazole 5                   0                    0 
Azithromycin 15 20 22 
Co-amoxiclav 30 34 36 
SE3                                                              Zone diameter (mm) 
Antibiotic Disc content (µg) Parent strain     Doxycycline -
adapted strain 
 S                 R  S                 R 
Doxycycline 30 19                                     10 
Ciprofloxacin 5 23                                  15 
Erythromycin 15 25                                      0 
Cefalexin 30 34                  30                  
Amoxicillin 25 32                 29                  
Trimethoprim 5 24 22 
Clarithromycin 15 30 27 
Linezolid 10 40 38 
Metronidazole 5                   0                     0 
Azithromycin 15 24 21 
Co-amoxiclav 30 37 39 
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Doxycycline-adapted strain was observed to have cross- resistance to ciprofloxacin, erythromycin and 
doxycycline in all five isolates (SE1-SE5) while remaining susceptible to cefalexin, amoxicillin, 
trimethoprim, clarithromycin, linezolid, azithromycin and co-amoxiclav. Doxycycline-adapted strains 
were resistant to metronidazole before and after being adapted to doxycycline (Table 2).  
 
                 
 
SE4                                                                   Zone diameter (mm) 
Antibiotic Disc content (µg) Parent strain 
  
Doxycycline 
- adapted  
 strain  
 S                 R   S                  R  
Doxycycline 30 17                                       8 
Ciprofloxacin 5 26                                     13 
Erythromycin 15 20                                       0 
Cefalexin 30 33                  25                    
Amoxicillin 25 30                 26                  
Trimethoprim 5 25 28 
Clarithromycin 15 36 31 
Linezolid 10 38 40 
Metronidazole 5                   0                        0 
Azithromycin 15 18 20 
Co-amoxiclav 30 38 40 
SE5                                                               Zone diameter (mm) 
 Antibiotic Disc content (µg) Parent strain  Doxycycline -
adapted strain   
 S              R   S                 R  
Doxycycline 30 14                                     10 
Ciprofloxacin 5 22                                    12 
Erythromycin 15 25                                      0 
Cefalexin 30 36                  34                      
Amoxicillin 25 31                 28                  
Trimethoprim 5 26 22 
Clarithromycin 15 31 28 
Linezolid 10 38 35 
Metronidazole 5                   0                     0 
Azithromycin 15 21 25 
Co-amoxiclav 30 38 40 
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Table 3. Antibiotic susceptibility pattern of S. epidermidis Parent strain and Ciprofloxacin adapted 
strain (sample: SE1-SE5) 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
                
 
 
 
 
 
 
SE1                                                                    Zone diameter (mm) 
Antibiotic Disc content (µg) Parent strain 
  
Ciprofloxacin -
adapted  
 strain  
 S                 R   S                  R  
Doxycycline 30 15                                       5 
Ciprofloxacin 5 20                                      9 
Erythromycin 15 26                                      10 
Cefalexin 30 37                  31                     
Amoxicillin 25 26                 28                  
Trimethoprim 5 22 26 
Clarithromycin 15 33 38 
Linezolid 10 34 31 
Metronidazole 5                   0                     0 
Azithromycin 15 20 19 
Co-amoxiclav 30 32 36 
SE2                                                             Zone diameter (mm) 
 Antibiotic Disc content (µg) Parent strain  Ciprofloxacin -
adapted strain   
 S              R   S                 R  
Doxycycline 30 18                                      7 
Ciprofloxacin 5 26                                    11 
Erythromycin 15 24                                     13 
Cefalexin 30 34                  29                      
Amoxicillin 25 31                 26                  
Trimethoprim 5 33 30 
Clarithromycin 15 31 29 
Linezolid 10 37 28 
Metronidazole 5                   0                    0 
Azithromycin 15 17 21 
Co-amoxiclav 30 32 34 
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SE3                                                              Zone diameter (mm) 
Antibiotic Disc content (µg) Parent strain      Ciprofloxacin -
adapted strain 
 S                 R  S                 R 
Doxycycline 30 22                                      13                    
Ciprofloxacin 5 27                                   15                    
Erythromycin 15 28                                      14 
Cefalexin 30 32                  28                  
Amoxicillin 25 29                 30                  
Trimethoprim 5 22 20 
Clarithromycin 15 27 25 
Linezolid 10 39 36 
Metronidazole 5                   0                     0 
Azithromycin 15 22 19 
Co-amoxiclav 30 38 35 
SE4                                                                   Zone diameter (mm) 
Antibiotic Disc content (µg) Parent strain 
  
Ciprofloxacin -
adapted  
 strain  
 S                 R   S                  R  
Doxycycline 30 17                                       9 
Ciprofloxacin 5 26                                     12 
Erythromycin 15 20                                      10 
Cefalexin 30 33                  31                    
Amoxicillin 25 29                 30                  
Trimethoprim 5 25 27 
Clarithromycin 15 35 32 
Linezolid 10 39 36 
Metronidazole 5                   0                        0 
Azithromycin 15 19 20 
Co-amoxiclav 30 38 39 
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Ciprofloxacin- adapted strain was observed to have cross- resistance to doxycycline, erythromycin and 
ciprofloxacin in all five isolates (SE1-SE5) while remaining susceptible to cefalexin, amoxicillin, 
trimethoprim, clarithromycin, linezolid, azithromycin and co-amoxiclav. Ciprofloxacin- adapted strains 
were resistant to metronidazole before and after being adapted to ciprofloxacin (Table 3).  
 
Table 4. Antibiotic susceptibility pattern of S. epidermidis Parent strain and Erythromycin adapted 
strain (sample: SE1-SE5) 
 
 
 
 
 
 
  
 
 
 
SE5                                                               Zone diameter (mm) 
 Antibiotic Disc content (µg) Parent strain  Ciprofloxacin  -
adapted strain   
 S              R   S                 R  
Doxycycline 30 16                                     9 
Ciprofloxacin 5 23                                   10 
Erythromycin 15 22                                    11 
Cefalexin 30 34                  32                      
Amoxicillin 25 32                 26                  
Trimethoprim 5 28 25 
Clarithromycin 15 32 29 
Linezolid 10 36 32 
Metronidazole 5                    0                     0 
Azithromycin 15 23 24 
Co-amoxiclav 30 39 42 
SE1                                                                    Zone diameter (mm) 
Antibiotic Disc content (µg) Parent strain 
  
Erythromycin -
adapted  
 strain  
 S                 R   S                  R  
Doxycycline 30 15                                        5 
Ciprofloxacin 5 27                                      10 
Erythromycin 15 22                                        0 
Cefalexin 30 32                  26                     
Amoxicillin 25 34                 32                  
Trimethoprim 5 25 27 
Clarithromycin 15 34 40 
Linezolid 10 36 33 
Metronidazole 5                    0                     0 
Azithromycin 15 24 21 
Co-amoxiclav 30 35 39 
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SE2                                                             Zone diameter (mm) 
 Antibiotic Disc content (µg) Parent strain  Erythromycin -
adapted strain   
 S              R   S                 R  
Doxycycline 30 14                                      6 
Ciprofloxacin 5 28                                    11 
Erythromycin 15 25                                      0 
Cefalexin 30 35                  29                      
Amoxicillin 25 31                 29                  
Trimethoprim 5 25 22 
Clarithromycin 15 32 29 
Linezolid 10 34 33 
Metronidazole 5                   0                    0 
Azithromycin 15 29 26 
Co-amoxiclav 30 37 36 
SE3                                                              Zone diameter (mm) 
Antibiotic Disc content (µg) Parent strain       Erythromycin -
adapted strain 
 S                 R  S                 R 
Doxycycline 30 29                                     12 
Ciprofloxacin 5 25                                  14         
Erythromycin 15 27                                      0 
Cefalexin 30 31                  39                  
Amoxicillin 25 33                 27                  
Trimethoprim 5 22 21 
Clarithromycin 15 29 24 
Linezolid 10 37 39 
Metronidazole 5                     0                     0 
Azithromycin 15 22 19 
Co-amoxiclav 30 36 38 
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Erythromycin - adapted strain was observed to be resistant to erythromycin and have cross- resistance 
to doxycycline and ciprofloxacin in all five isolates (SE1-SE5) while remaining susceptible to cefalexin, 
amoxicillin, trimethoprim, clarithromycin, linezolid, azithromycin and co-amoxiclav. Erythromycin - 
adapted strains were resistant to metronidazole before and after being adapted to erythromycin 
(Table 4). 
 
SE4                                                                   Zone diameter (mm) 
Antibiotic Disc content (µg) Parent strain 
  
Erythromycin  -
adapted  
 strain  
 S                 R   S                  R  
Doxycycline 30 18                                       8 
Ciprofloxacin 5 26                                     13 
Erythromycin 15 20                                       0 
Cefalexin 30 33                  31                   
Amoxicillin 25 32                 34                  
Trimethoprim 5 29 30 
Clarithromycin 15 34 30 
Linezolid 10 35 36 
Metronidazole 5                    0                        0 
Azithromycin 15 21 22 
Co-amoxiclav 30 39 37 
SE5                                                               Zone diameter (mm) 
 Antibiotic Disc content (µg) Parent strain  Erythromycin -
adapted strain   
 S              R   S                 R  
Doxycycline 30 19                                      5 
Ciprofloxacin 5 21                                    12 
Erythromycin 15 28                                      0 
Cefalexin 30 35                  32                      
Amoxicillin 25 28                 26                  
Trimethoprim 5 25 20 
Clarithromycin 15 33 27 
Linezolid 10 34 31 
Metronidazole 5                    0                     0 
Azithromycin 15 19 22 
Co-amoxiclav 30 37 39 
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Table 5. Antibiotic susceptibility pattern of S. epidermidis Parent strain and Cefalexin adapted strain 
(sample: SE1-SE5) 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SE1                                                                    Zone diameter (mm) 
Antibiotic Disc content (µg) Parent strain 
  
Cefalexin - adapted  
 strain  
 S                 R   S                  R  
Doxycycline 30 13                   9 
Ciprofloxacin 5 25                 21 
Erythromycin 15 23                  20 
Cefalexin 30 34                  30                     
Amoxicillin 25 30                 32                  
Trimethoprim 5 27 29 
Clarithromycin 15 36 39 
Linezolid 10 35 30 
Metronidazole 5                     0                     0 
Azithromycin 15 22 21 
Co-amoxiclav 30 38 40 
SE2                                                             Zone diameter (mm) 
 Antibiotic Disc content (µg) Parent strain  Cefalexin - adapted 
strain   
 S              R   S                 R  
Doxycycline 30 15                  10 
Ciprofloxacin 5 23                 19 
Erythromycin 15 24                  20 
Cefalexin 30 29                  32                      
Amoxicillin 25 33                 25                  
Trimethoprim 5 28 24 
Clarithromycin 15 30 27 
Linezolid 10 33 32 
Metronidazole 5                    0                    0 
Azithromycin 15 19 21 
Co-amoxiclav 30 35 37 
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SE3                                                              Zone diameter (mm) 
Antibiotic Disc content (µg) Parent strain  Cefalexin - adapted 
strain 
 S                 R  S                 R 
Doxycycline 30 21                  24 
Ciprofloxacin 5 24               20 
Erythromycin 15 27                  26 
Cefalexin 30 33                  32                  
Amoxicillin 25 32                 29                  
Trimethoprim 5 26 24 
Clarithromycin 15 31 26 
Linezolid 10 37 39 
Metronidazole 5                     0                     0 
Azithromycin 15 23 22 
Co-amoxiclav 30 37 40 
SE4                                                                   Zone diameter (mm) 
Antibiotic Disc content (µg) Parent strain 
  
Cefalexin 
- adapted  
 strain  
 S                 R   S                  R  
Doxycycline 30 19                  22 
Ciprofloxacin 5 23                 24 
Erythromycin 15 19                  25 
Cefalexin 30 31                  28                    
Amoxicillin 25 29                 25                  
Trimethoprim 5 27 30 
Clarithromycin 15 37 34 
Linezolid 10 39 37 
Metronidazole 5                     0                        0 
Azithromycin 15 22 28 
Co-amoxiclav 30 35 39 
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Cefalexin - adapted strains had no cross- resistance in any of the five isolates (SE1-SE5). The adapted 
strain remained susceptible to doxycycline, ciprofloxacin, erythromycin, cefalexin, amoxicillin, 
trimethoprim, clarithromycin, linezolid, azithromycin and co-amoxiclav. Cefalexin - adapted strains 
were resistant to metronidazole before and after being adapted to cefalexin (Table 5). 
 
Table 6. Antibiotic susceptibility pattern of S. epidermidis Parent strain and Amoxicillin adapted 
strain (sample: SE1-SE5) 
 
 
 
 
 
 
  
 
 
SE5                                                               Zone diameter (mm) 
 Antibiotic Disc content (µg) Parent strain  Cefalexin - adapted 
strain 
 S              R   S                 R  
Doxycycline 30 17                 21 
Ciprofloxacin 5 24                 26 
Erythromycin 15 26                  28                     
Cefalexin 30 37                  36                      
Amoxicillin 25 29                 27                  
Trimethoprim 5 29 25 
Clarithromycin 15 34 32 
Linezolid 10 39 37 
Metronidazole 5                   0                     0 
Azithromycin 15 19 22 
Co-amoxiclav 30 36 38 
SE1                                                                    Zone diameter (mm) 
Antibiotic Disc content (µg) Parent strain 
  
Amoxicillin - adapted  
 strain  
 S                 R   S                  R  
Doxycycline 30 25                  28 
Ciprofloxacin 5 30                 29          
Erythromycin 15 33                  27                    
Cefalexin 30 34                  32                     
Amoxicillin 25 30                 28                  
Trimethoprim 5 24 26 
Clarithromycin 15 34 39 
Linezolid 10 36 32 
Metronidazole 5                   0                     0 
Azithromycin 15 24 21 
Co-amoxiclav 30 39 36 
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SE2                                                             Zone diameter (mm) 
 Antibiotic Disc content (µg) Parent strain  Amoxicillin - adapted 
strain   
 S              R   S                 R  
Doxycycline 30 25                  22                   
Ciprofloxacin 5 30                 24                
Erythromycin 15 26                 27                    
Cefalexin 30 33                  32                      
Amoxicillin 25 30                 26                  
Trimethoprim 5 28 21 
Clarithromycin 15 33 25 
Linezolid 10 36 32 
Metronidazole 5                   0                    0 
Azithromycin 15 22 24 
Co-amoxiclav 30 38 35 
SE3                                                              Zone diameter (mm) 
Antibiotic Disc content (µg) Parent strain  Amoxicillin - adapted 
strain 
 S                 R  S                 R 
Doxycycline 30 27                  33 
Ciprofloxacin 5 30               21 
Erythromycin 15 31                  29 
Cefalexin 30 31                  28                  
Amoxicillin 25 33                 27                  
Trimethoprim 5 22 18 
Clarithromycin 15 28 26 
Linezolid 10 38 40 
Metronidazole 5                   0                     0 
Azithromycin 15 21 19 
Co-amoxiclav 30 34 37 
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Amoxicillin - adapted strains had no cross- resistance in any of the five isolates (SE1-SE5). The adapted 
strain remained susceptible to doxycycline, ciprofloxacin, erythromycin, cefalexin, amoxicillin, 
trimethoprim, clarithromycin, linezolid, azithromycin and co-amoxiclav. Amoxicillin - adapted strains 
were resistant to metronidazole before and after being adapted to Amoxicillin (Table 6). 
 
 
  
SE4                                                                   Zone diameter (mm) 
Antibiotic Disc content (µg) Parent strain 
  
Amoxicillin - adapted  
 strain  
 S                 R   S                  R  
Doxycycline 30 28                 27                     
Ciprofloxacin 5 24                 22                   
Erythromycin 15 23                 21                    
Cefalexin 30 31                  29                    
Amoxicillin 25 28                 27                  
Trimethoprim 5 23 22 
Clarithromycin 15 34 31 
Linezolid 10 36 34 
Metronidazole 5                     0                        0 
Azithromycin 15 16 21 
Co-amoxiclav 30 36 39 
SE5                                                               Zone diameter (mm) 
 Antibiotic Disc content (µg) Parent strain  Amoxicillin - adapted 
strain 
 S              R   S                 R  
Doxycycline 30 26                  24          
Ciprofloxacin 5 28                 26                  
Erythromycin 15 29                  27                     
Cefalexin 30 34                  36                      
Amoxicillin 25 36                 34                  
Trimethoprim 5 29 27 
Clarithromycin 15 33 30 
Linezolid 10 37 35 
Metronidazole 5                   0                     0 
Azithromycin 15 19 21 
Co-amoxiclav 30 40 37 
  
64 
 
Sample SE1 vs 
Antibiotic: 
Parent strain MIC 
mg/mL 
Passage ‘9’ strain MIC 
mg/mL 
Resistant                 Y/N 
Amoxicillin 4 2  
Doxycycline 16 64  
Ciprofloxacin 2 8  
Erythromycin 2 ≥128 Y 
Cefalexin 2 4  
Sample SE2 vs 
Antibiotic: 
Parent strain MIC 
mg/mL 
Passage ‘9’ strain MIC 
mg/mL 
Resistant                   Y/N 
Amoxicillin 4 16  
Doxycycline 16 64  
Ciprofloxacin 2 8  
Erythromycin 2 ≥128 Y 
Cefalexin 2 8  
Sample SE3 vs 
Antibiotic: 
Parent strain MIC 
mg/mL 
Passage ‘9’ strain MIC 
mg/mL 
Resistant                   Y/N 
Amoxicillin 4 8  
Doxycycline 16 64  
Ciprofloxacin 2 8  
Erythromycin 2 ≥128 Y 
Cefalexin 2 4  
Sample SE4 vs 
Antibiotic: 
Parent strain MIC 
mg/mL 
Passage ‘9’ strain MIC 
mg/mL 
Resistant                   Y/N 
Amoxicillin 4 2  
Doxycycline 16 64  
Ciprofloxacin 2 8  
Erythromycin 2 ≥128 Y 
Cefalexin 2 4  
 
	
	
  
Sample        SE5        vs 
Antibiotic: 
Parent strain MIC 
mg/mL 
Passage ‘9’ strain MIC 
mg/mL 
Resistant                 Y/N 
Amoxicillin 4 8  
Doxycycline 4 16  
Ciprofloxacin 2 8  
Erythromycin 2 ≥128 Y 
Cefalaxin 2 4  
Table 7. Difference in MIC between Parent and P9 strains (SE1 –SE5)  
 
3.2	MIC		
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Cross resistant 
MIC tests. 
Sample (passage 
9) vs antibiotic 
Amoxicillin  
MIC 
mg/mL 
Doxycycline 
MIC 
mg/mL 
Erythromycin 
MIC 
mg/mL 
Cefalexin 
MIC 
mg/mL 
SE1 cipro 8 8 8 8 
SE2 cipro 8 8 8 8 
SE3 cipro 8 8 8 8 
SE4 cipro 8 8 8 8 
SE5 cipro 8 8 8 64 
Cross resistant 
MIC tests. 
Sample (passage 
9) vs antibiotic 
Ciprofloxacin 
MIC 
mg/mL 
Amoxicillin 
MIC 
mg/mL 
Erythromycin 
MIC 
mg/mL 
Cefalexin 
MIC 
mg/mL 
SE1 doxy 32 64 32 32 
SE2 doxy 32 32 64 32 
SE3 doxy 32 32 32 32 
SE4 doxy 32 32 32 32 
SE5 doxy 32 32 32 32 
Cross resistant 
MIC tests. 
Sample (passage 
9) vs antibiotic 
Ciprofloxacin 
MIC 
mg/mL 
Doxycycline 
MIC 
mg/mL 
Amoxicillin  
MIC 
mg/mL 
Cefalexin 
MIC 
mg/mL 
SE1 eryth 2 4 4 2 
SE2 eryth 2 16 8 32 
SE3 eryth 2 4 4 32 
SE4 eryth 2 16 16 2 
SE5 eryth 2 16 4 2 
Cross resistant 
MIC tests. 
Sample (passage 
9) vs antibiotic 
Ciprofloxacin 
MIC 
mg/mL 
Doxycycline 
MIC 
mg/mL 
Erythromycin 
MIC 
mg/mL 
Amoxicillin 
MIC 
mg/mL 
SE1 cefal 2 2 2 2 
SE2 cefal 2 2 2 2 
SE3 cefal 2 2 ≥128 2 
SE4 cefal 2 2 ≥128 2 
SE5 cefal 2 2 ≥128 2 
  
Cross resistant 
MIC tests. 
Sample (passage 
9) vs antibiotic 
Ciprofloxacin 
MIC 
mg/mL 
Doxycycline 
MIC 
mg/mL 
Erythromycin 
MIC 
mg/mL 
Cefalexin 
MIC 
mg/mL 
SE1 amoxi  8 32 8 8 
SE2 amoxi  8 8 8 8 
SE3 amoxi 8 8 8 8 
SE4 amoxi 8 8 8 8 
SE5 amoxi 8 8 8 8 
Table 8. Cross resistance based on MIC between P9 strains (SE1 –SE5)  
 
3.3	Cross	resistance	
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SEERYTH strains from all five samples exhibited a large increase in MIC sensitivity to erythromycin by a 
64-fold increase. High amount of cross-resistance (4- to 64-fold) was observed in SEERYTH MICs from 
SE2 and SE3 samples when exposed to cefalexin. Also, SE4 and SE5 SEERYTH MICs revealed high level of 
cross-resistance (8- to 64-fold) when exposed to doxycycline. SEDOX MICs from SE1-SE5 showed an 
average amount of increase in resistance to doxycycline by 2- to 8-fold. In addition to this, SEDOX MICs 
displayed slight cross-resistance to erythromycin, ciprofloxacin, amoxicillin and cefalexin with MICs of 
32 mg/mL. However, SEDOX MIC from sample SE1 revealed high cross-resistance (2-to 64- fold) when 
exposed to amoxicillin and SE2 SEDOX MIC also showed high level (2-to 64- fold) of cross-resistance 
when exposed to erythromycin. Moreover, SE1-SE5 MICs of SECIPRO displayed a moderate 4-fold 
increase in resistance to ciprofloxacin. SECIPRO strain from sample SE5 showed high level (2-to 64- fold) 
of cross-resistance when exposed to cefalexin. SECEFAL from samples SE3, SE4 and SE5 revealed high 
cross-resistance (64- fold) when exposed to erythromycin. SEAMOXI strain from sample SE1 presented 
high cross-resistance to doxycycline MIC by 4- to 64-fold. 
All antibiotic-adapted strains of S. epidermidis exhibited cross-resistance: 8 to doxycycline (DOX), 5 to 
ciprofloxacin (CIPRO), 10 to erythromycin (ERYTH), 3 to cefalexin (CEFAL), and 1 to amoxicillin (AMOXI) 
(Table 9). In sample SE1, SEDOX formed cross resistance to amoxicillin and the strain SEAMOXI formed 
cross resistance to doxycycline. In sample SE2, SEDOX formed cross resistance to erythromycin, SEERYTH 
formed cross resistance to cefalexin and SECEFAL formed cross resistance to erythromycin. In sample 
SE3, SEERYTH formed cross resistance to cefalexin and SECEFAL formed cross resistance to erythromycin. 
In sample SE4, SEERYTH formed cross resistance to doxycycline and SECEFAL formed cross resistance to 
erythromycin. In sample SE5, SECIPRO formed cross resistance to cefalexin, SEERYTH formed cross 
resistance to doxycycline and SECEFAL formed cross resistance to erythromycin (Table 9). 
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SE2 DOX CIPRO ERYTH CEFAL AMOXI 
SE S S S S S 
SEDOX R S R S S 
SECIPRO S R S S S 
SEERYTH S S R R S 
SECEFAL S S R S S 
SEAMOXI S S S S S 
SE3 DOX CIPRO ERYTH CEFAL AMOXI 
SE S S S S S 
SEDOX R S S S S 
SECIPRO S R S S S 
SEERYTH S S R R S 
SECEFAL S S R S S 
SEAMOXI S S S S S 
SE4 DOX CIPRO ERYTH CEFAL AMOXI 
SE S S S S S 
SEDOX R S S S S 
SECIPRO S R S S S 
SEERYTH R S R S S 
SECEFAL S S R S S 
SEAMOXI S S S S S 
SE5 DOX CIPRO ERYTH CEFAL AMOXI 
SE S S S S S 
SEDOX R S S S S 
SECIPRO S R S R S 
SEERYTH R S R S S 
SECEFAL S S R S S 
SEAMOXI S S S S S 
SE1 DOX CIPRO ERYTH CEFAL AMOXI 
SE S S S S S 
SEDOX R S S S R 
SECIPRO S R S S S 
SEERYTH S S R S S 
SECEFAL S S S S S 
SEAMOXI R S S S S 
S-sensitive R-resistant 
Table 9. Cross resistance of antibiotic-adapted strains to antibiotics based on MIC  
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3.4	Biofilms	
The relative biofilm-forming unit was calculated, showing a significant difference (p <0.05) between 
the biofilm of SE1 parent strain and antibiotic-adapted strains of S. epidermidis (SEERYTH and SEDOX) 
(Figure 11. A, B, & C). In sample SE1, there was a decrease in biofilm formation by the following 
antibiotic-adapted strains (at 24 h SEERYTH = 12.5%; at 48 h SEERYTH = 16%, SEDOX = 35.6%); (at 72 
h SEERYTH = 8.4%, SEDOX = 20.6%) compared to the parent strain. On the other hand, sample SE1 
displayed an increase in the amount of biofilm formed by the subsequent adapted strains (at 24 h 
SEDOX =142.7%; at 48 h SECIPRO =11.7%) when compared to the parent strain. From 24 h to 72 h the 
parent strain continues to grow in large amount overtime and significantly more than SEERYTH biofilm. 
However, SEERYTH does not have the same progressive trend as the parent strain, there was a 
decrease in biofilm formation from 24 h to 48 h and an increase in biofilm formation during 72 h 
growth period (Figure 11. A, B, & C). The 48 h parent strain biofilm was significantly thicker than 48 h 
SECIPRO biofilm. SEDOX biofilm was significantly denser than the parent S. epidermidis and SEERYTH 
biofilms when grown for 24 h (Figure 5. A). However, during 48 h and 72 h growth periods, SEDOX 
biofilms grew significantly the least compared to the parent S. epidermidis and SEERYTH biofilms 
(Figure 11. B & C). 
Sample SE2 antibiotic-adapted strains formed significantly less biofilm (at 48 h SECIPRO = 42.4%; at 72 
h SECIPRO = 7%) in comparison to the parent strain. Also, substantial biofilm was significantly formed 
by the following SE2 adapted strains (at 24 h SECIPRO = 17.6%, SEDOX = 27%; at 48 h SEERYTH = 
101.5%, SEDOX = 45%; at 72 h SEERYTH = 64.3%, SEDOX = 188.5%) when compared to the parent 
strains. 24 h parent strain grew significantly less than SECIPRO and SEDOX. 48 h parent strain grew 
significantly less than SEERYTH and SEDOX yet grew significantly more than SECIPRO. 72 h parent 
strain grew significantly more than SECIPRO, but less than SEERYTH and SEDOX biofilms. SEERYTH 
biofilm grew significantly more than the parent strain, SECIPRO and SEDOX biofilms when grown for 
48 h. However, SEERYTH biofilm grew significantly more than SECIPRO biofilm and significantly less 
than SEDOX biofilm during 72 h growth period. 24 h SECIPRO biofilm grew significantly more than the 
parent strain yet less than SEDOX biofilm. During 48 h and 72h growth periods, SECIPRO biofilm grew 
significantly the least compared to parent strain, SEERYTH and SEDOX biofilms. During 24 h and 72 h 
growth periods, SEDOX biofilm was observed to grow significantly the most compared to parent strain 
and SEERYTH biofilms. However, during 48 h SEDOX biofilm grew significantly less than SEERYTH, yet 
significantly more than the parent strain and SECIPRO biofilms.  
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Figure 11. Mean relative biofilm units of five S. epidermidis samples (SE1 - SE5) with error 
bars. Significant differences (p <0.05) are shown between the mean relative biofilm forming 
capacity of the various antibiotic-adapted strains and parent strains over time. 
 
0
1
2
3
4
5
6
7
8
SE1 SE2 SE3 SE4 SE5
M
ea
n 
Rr
la
tiv
e 
Bi
of
ilm
 U
ni
t
S. epidermidis Isolates
S. epidermidis biofilm growth in 48 h
Parent strain SEERYTH SECIPRO SEDOX
B 
0
1
2
3
4
5
6
7
8
SE1 SE2 SE3 SE4 SE5M
ea
n 
Re
la
tiv
e 
Bi
of
ilm
 U
ni
t
S. epidermidis Isolates
S. epidermidis biofilm growth in 72 h
Parent strain SEERYTH SECIPRO SEDOX
C 
    * 
 * 
A 
  *  * 
 *  * 
* 
  * 
 * 
    * 
   * 
 * * 
 
* 
* 
  * 
* 
* 
* 
 * 
 
 *  *   * 
* 
 * 
* 
   * 
* * * 
 
* 
* 
* 
* 
 * 
  
70 
 
    
Less biofilm was significantly formed by the sample SE3 adapted strains (at 24 h SEERYTH = 71.6%; at 48 
h SEERYTH = 33.7%, SECIPRO = 40.7%, SEDOX = 23%; at 72 h SEERYTH = 9%, SECIPRO = 23.9%, SEDOX = 13.5%) in 
comparison to the parent strain. In contrast, more biofilm was significantly formed by the resulting 
SE3 adapted strain (at 24 h SECIPRO = 54%) opposed to the parent strain. From 24 h to 72 h the parent 
strain was significantly larger than SEERYTH biofilm as it continues to grow in larger amounts. However, 
SEERYTH biofilm significantly increased in density from 24 h to 72 h. During 24 h, SECIPRO biofilm 
significantly grew the most compared to the parent strain and SEERYTH biofilms. However, from 48 h to 
72 h, SECIPRO significantly grew the least compared to parent strain, SEERYTH and SEDOX biofilms. SEDOX 
biofilm displayed a significant increase in growth from 48 h to 72 h, it grew significantly more than 
SECIPRO and SEERYTH. 
In sample SE4, biofilm formation was significantly produced far less by the subsequent adapted strains 
(at 24 h SECIPRO = 25.7%; at 48 h SECIPRO = 37.7%) compared to the parent strain. SE4 sample also showed 
a significant increase in biofilm formation by the following adapted strains (at 48 h SEERYTH = 57%, SEDOX 
= 58.4%; at 72 h SEDOX = 14.7%, SECIPRO = 147%) in comparison to the parent strain. From 24 h to 48 h 
the parent strain biofilm was observed to grow increasingly and significantly more than SECIPRO. 48 h 
SEERYTH biofilm significantly grew more than parent strain and SECIPRO. SECIPRO significantly decreased in 
biofilm growth from 24 h to 48 h and then increased when grown for 72 h. SECIPRO biofilm was observed 
to grow significantly the most during 72 h whereas it hardly grew during 48 h. SEDOX biofilm density 
remained the same during 48 h to 72 h yet significantly more than the parent strain during both 48 h 
to 72 h growth periods. 
Sample SE5 had significantly smaller amount of biofilm produced by the subsequent adapted strains 
(at 24 h SECIPRO = 39.6%, SEDOX = 57.4%; at 48 h SECIPRO = 43.3; at 72 h SECIPRO = 26.6%) when compared 
to the parent strain. Nevertheless, substantial biofilm was significantly formed by the following 
adapted strains (at 48 h SEDOX = 56.6%; at 72 h SEDOX = 31.7%) in comparison to the parent strain. From 
24 h to 72 h the parent strain significantly grew more than SECIPRO. From 48 h to 72 h SECIPRO biofilm 
grew significantly less than SEDOX biofilm but grew significantly more than 24 h SEDOX biofilm. SEDOX 
biofilm significantly increased in density from 48 h to 72 h. 
 
 
 
 
* 
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3.5	Relative	fitness:	P0	vs	P9	strains	
The overall productivity (CFU per milliliter) of P9 after 24 h of growth was significantly lower than that 
of P0. This deficit in growth was substantially more pronounced when the strains were grown in 
competition (Figure. 12). The relative Darwinian fitness (W) levels of P0 and P9 were compared when 
grown separately and when in competition with each other (Figure. 12). A relative fitness of 1 implies 
no fitness effect between strains, a value of below 1 indicates impaired fitness, and a value above 1 
specifies enhanced fitness.  
The relative fitness (W) of SEERYTH P9 to P0 during individual growth was 1.02, compared to 1.35 during 
competition. Thus, in a non-competitive environment SEERYTH P9 grew 1.8% slower than P0, whereas 
when in a competitive environment, SEERYTH P9 grew 22.9% slower than P0. P0 was observed to be 
significantly fitter than SEERYTH P9 when grown together. 
The relative fitness (W) of SEDOX P9 to P0 during individual growth was 1.26, compared to 0.38 during 
competition. Thus, in a non-competitive environment SEDOX P9 grew 28.2% slower than P0, whereas 
when in a competitive environment, SEDOX P9 grew 58.6% slower than P0. P0 was significantly fitter 
than SEDOX P9 when grown separately and together. 
The relative fitness (W) of SECIPRO P9 to P0 during individual growth was 1.4, compared to 0.45 during 
competition. Thus, in a non-competitive environment SECIPRO P9 grew 49.4% slower than P0, whereas 
when in a competitive environment, SECIPRO P9 grew 55.9% slower than P0. P0 was significantly fitter 
than SECIPRO P9 when grown separately.  
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* * 
Figure 12. Mean colony forming units with standard deviation error bars (p <0.05). Significant 
differences in the mean colony forming capacity amongst the various antibiotic-adapted strains 
when compared to the parent strains at 24 h. SEERYTH axenic p-value= 0.2 and binary  
p-value <0.043. B. SEDOX axenic p-value < 0.0001 and binary p-value < 0.0001. C. SECIPRO axenic  
p-value < 0.0001 and binary p-value < 0.0002. 	
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3.6	Galleria	mellonella	(wax	worm)	virulence	assay 
Total of 540 larvae tested from group A & B. Data of waxworm survival over two-week period in group 
A and B shown on the next page. Two PBS injected worms died on Day 4 for both group A & B.  18 
non-treated category worms remained healthy throughout the experiments for both groups.  
SEERYTH strain was significantly more virulent than SE and SEDOX strain in Figure 13A. 7 SEERYTH infected 
waxworms started dying from day 2 with 8 SEERYTH waxworm surviving on day 4 (Figure 13A). Whereas, 
on average 14 SEDOX infected waxworms survived on day 4, however, only 2 SEDOX waxworms survived 
on average. SE infected waxworm started dying on day 3, 12 waxworms survived on day 4. 
SEERYTH strain was significantly more virulent than SE and SEDOX strain in Figure 13B. Most SEERYTH and 
SEDOX infected waxworms started dying from day 2.  Many SEERYTH infected waxworms did not survive 
on day 4 with only 4 waxworms surviving on average. Moreover, 7 SEDOX infected waxworms were able 
to survive on day 4 (Figure 13B). Only few of the SE waxworms died on day 4 with 15 waxworms 
surviving on day 4. 
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SE Day 0 Day 1 Day 2 Day 3 Day 4 
SE1 18 18 18 11 12 
SE2 18 18 18 12 12 
SE3 18 18 18 12 12 
Mean 18 18 18 11.66666667 12 
SEDOX      
SE1 18 18 15 5 3 
SE2 18 18 16 4 2 
SE3 18 18 13 2 1 
Mean 18 18 14.66666667 3.666666667 2 
SEERYTH      
SE1 18 18 10 9 7 
SE2 18 18 11 11 8 
SE3 18 18 12 11 9 
Mean 18 18 11 10.33333333 8 
SE Day 0 Day 1 Day 2 Day 3 Day 4 
SE1 18 18 18 18 15 
SE2 18 18 18 18 14 
SE3 18 18 18 18 16 
Mean 18 18 18 18 15 
SEDOX      
SE1 18 18 16 9 6 
SE2 18 18 15 9 7 
SE3 18 18 18 7 8 
Mean 18 18 16.33333333 8.333333333 7 
SEERYTH      
SE1 18 18 14 11 4 
SE2 18 18 13 10 5 
SE3 18 18 15 8 3 
Mean 18 18 14 9.666666667 4 
Surviving larvae SE SEERYTH SEDOXY PBS NTC 
Mean of A 12 8 2 16 18 
Mean of B 15 4 7 16 18 
Mean of A & B 13.5 6 4.5 16 18 
P-value  0.047733 0.045431   
Table 12. One-tailed T-test on surviving groups of larvae  
 
Table 10. Number of surviving larvae over 4 days following inoculation with SE, SEDOX and SEERYTH 
strains 
Table 11. Number of surviving larvae over 4 days following inoculation with SE, SEDOX and SEERYTH 
Surviving larvae in Group A  
Surviving larvae in Group B  
Surviving larvae in Group B  
Average surviving larvae in Group A & B  
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The assessment of survival rates following G. mellonella infection showed that SEERYTH and SEDOXY 
strains were significantly virulent compared to S. epidermidis parent strains with p-value of 0.0477 
and 0.0454, respectively.  
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
Figure 13. Two independent test results showing a survival curve of the daily number of 
surviving larvae following G. mellonella infection assay KEY: Parent strains (SE– S. 
epidermidis; Antibiotic-adapted strains (SEERYTH, SEDOX); NTC– Non-treated category; PBS– 
Phosphate buffered saline.  
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CHAPTER	4	
4.0	Discussion		
Although there are currently several preventative strategies in place to control infection and closely 
observed trends in antibiotic resistance, the S. epidermidis infection rate is still very high and continues 
to occur in hospitals and care homes (Otto, 2012; Brown & Clarke, 2017).  This research work is based 
upon the characterisation of S. epidermidis taken from human skin, adapted to antibiotics to gain 
insight on the virulence of antibiotic adapted S. epidermidis. This research highlights the potential 
significance antibiotic adapted S. epidermidis may have in prospective diagnosis when treating 
infected patients. Many studies have determined that opportunistic pathogens such as S. epidermidis 
have virulence factors that commonly assist in advanced bacterial growth and/or spread within or 
between hosts (Brown, Cornforth & Mideo, 2012). 
The technique used to achieve antibiotic susceptibility profiling involved MICs and disk diffusion tests 
to assess characteristics that link directly to the problem of over resistance and the development of 
cross-resistance due to repetitive use of antibiotics. The mentioned methods were inexpensive, high-
throughput and rapid which provide efficient data that supports the risk of antibiotic resistance 
evolving (Ferreira et al, 2017). However, the zone of inhibition results from disk diffusion tests can be 
influenced by the thickness or viscidness of the culture medium, the antibiotic concentration the filter 
disc has absorbed, how fast the antibiotic is diffused and how it interacted with the medium as well 
as how sensitive the bacteria is to the antibiotic. Also, if an antibiotic is observed to have a strong 
antibiotic capacity it might not be suitable for medical use as it can possibly cause dangerous side 
effects in the human biological system. Variables that may influence the reliability of these tests may 
also limit the interpretation of MIC data. This may occur due to in vitro experiment conditions not 
having the capacity to replicate the host habitat (Srinivasan et al., 2017).  
4.1	Antibiotic	resistant	strains	
This research work investigated antimicrobial activity of eleven antibiotics against S. epidermidis 
extracted from the human skin microflora. All bacterial strains developed resistance to erythromycin, 
while being susceptible to 9 other tested antibiotics except metronidazole. The five isolates (SE1 - SE5; 
SEDOX SECIPRO SEERYTH SECEFAL SEAMOXI) were found to be multi-resistant, established by the Kirby-Bauer 
disc diffusion method and MIC results. The antibiogram of the parent and antibiotic-adapted isolates 
was produced using this standard method as it is constantly and generally utilised for antibiotic 
sensitivity tests in medical laboratories worldwide (EUCAST, 2019). Parent isolates of S. epidermidis 
that were originally only sensitive to certain antibiotics later formed resistance to them after nine 
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serial passages (P9); serial passage eventually led to the arise of resistant antibiotic-adapted strains, 
determined by the absence of zone of inhibition. Resistance is not the matter of if but only of when. 
There is a constant need for new or improved antibiotics to treat the bacterial populations that come 
back in resistant form after the first wave of antibiotic treatments. In this project the following 
antibiotics; (1) doxycycline, (2) erythromycin and (3) ciprofloxacin forced S. epidermidis parent strain 
to adapt.  
Penicillin continues to be the most exploited antibiotic while a group of tetracycline antibiotics follow 
up as the second most commoly used antibiotic universally (van Hoek et al., 2011). Doxycycline (1) is 
a broad-spectrum antibiotic that interrupts the bacteria capability to produce proteins that are 
important for bacterial growth, replication and to form colonies. Moreover, few bacterial variants 
have become resistant to this drug, hence, reducing the efficacy of the treatment for certain set of 
bacterial infections (Otto, 2012). The mode of action for antimicrobial reaction of tetracycline heavily 
rely on the disruption of translated proteins within the bacteria, hence, destroying the bacteria 
capacity to duplicate and develop. Nevertheless, the polypeptide translation process can be 
disarranged within mitochondria belonging to eukaryotic cells, the metabolism appear to be impaired 
and may cause death, thus, damaging the validity of results from the experiment. Plasmid containing 
tet genes including tetL and tetK can encode tetracycline resistance. Similarly, genes tetO and tetM 
situated within transposons or chromosome can also encode tetracycline resistance. High percentage 
of around 92% has been reported for tetK gene, however just a single bacterial strain had displayed 
the tetM gene. Various research articles have described the simultaneousness of tetK and tetM genes 
within Staphylococcal species (Duran et al., 2012; Schiwon et al., 2013).  
Additionally, some studies showed that S. epidermidis resistance can be due to the existence of 
panton-valentine leucocidin gene (Stamatiou et al., 2013) that is specific to particular strains, these 
Staphylococcal isolates yield and secrete an extracellular toxic two-structured substance. Several 
Staphylococci strains have recently become resistant to tetracycline antibiotics. Doxycycline is a highly 
lipophilic analogue with an increased Staphylococcal activity, previously used in treating urinary tact 
infections caused by  S. saprophyticus. The tetracycline resistant strains that contain ribosomal 
protection (TetM) are resistant to both minocycline and tetracycline, whereas those tetracycline 
resistant strains that have an active efflux (TetK) are only susceptible to minocycline (Stamatiou et al., 
2013).  
Erythromycin (2) is a broad-spectrum macrolide antibiotic which functions against a wide-range of 
microbes. In regard to the genotype of Staphylococci, it forms resistance to erythromycin due to the 
few genes it carries, several studies (Duran et al., 2012; Schiwon et al., 2013) have identified the 
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prevalence of the ermC gene in Staphylococci including the study carried out by Águila-Arcos et al. 
(2017). The ermC gene was identified in all the clinical Staphylococcus strains while 72% of the isolates 
harbored the ermB gene. Similarly,  Zmantar et al. (2011) research displayed a low frequency 
of ermB gene in S. epidermidis strains. Vimberga et al. (2019) research also found all S. epidermidis 
strains to be resistant to erythromycin, genome sequencing results showed that all of the S. 
epidermidis strains carried mecA, fosA, blaZ, vgaB, and vatB resistance genes. Additionally, ermA 
resistance gene was also found in one of the S. epidermidis strains. The presence of macrolide 
resistance genes positively correlates to the resistance of the isolates to erythromycin. 
Ciprofloxacin (3) is a broad-spectrum fluoroquinolone antibiotic which works to kill Gram negative and 
Gram positive microbes (Marco et al., 2017). The functionality of ciprofloxacin rely on the inhibition 
of DNA gyrase enzyme which is a type II topoisomerase. It is important for ciprofloxacin to split 
microbial DNA to stop the cell from dividing/replicating (Marco et al., 2017). Ciprofloxacin 
antimicrobial activity is not only caused by inhibiting DNA gyrase (topoisomerase II) but also inhibiting 
type IV topoisomerase as it is needed for microbial DNA replication, recombination, transcription and 
repair (Marco et al., 2017). 
Divakarab et al., (2017) research study showed that S. epidermidis from dental infections (caries) had 
higher ciprofloxacin and erythromycin resistance compared to healthy individuals. These 
ciprofloxacin and erythromycin resistance isolates had mecA gene present and virulence genes 
e.g. sea and seb significantly more than healthy individual isolates. As expected, both groups of S. 
epidermidis isolates from dental caries and healthy individuals had different SCCmec types, which may 
be the case for P0 parent strains and P9 antibiotic adapted strains in this study. Previous research 
studies have identified various substantial relations between bacterial strains’ SCCmec types and 
antibiotic resistance as well as virulence genes (Divakarab et al., 2017). SCCmec types, III and IV were 
found to be more resistant than other SCCmec types, mostly resistant to ciprofloxacin 
and erythromycin, carrying sea, seg and sei (Divakarab et al., 2017).  
4.2	Persister	cells	in	biofilm	
Biofilm formation was studied in this research via absorbance of biofilm produced on a 96-well 
polystyrene microtiter plate. The obtained biofilm data was divided by the planktonic bacteria OD, to 
find the relative biofilm-forming units, which is an accurate representation of biofilm formed, 
regardless of planktonic bacteria growth (Stipetic et al., 2016). Due to the significant differences seen 
in the mean relative biofilm-forming units of the antibiotic-adapted S. epidermidis strains and the 
parent strains, it can be suggested that antibiotic adaptation decreased the ability of the bacteria to 
produce biofilm in this particular study. The antibiotic-adapted S. epidermidis (P9) strains displayed 
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low significant (p < 0.05) fitness level to form biofilms with reduced competence compared to the 
parent strains. For example, SEERYTH biofilm significantly increased in density from 24 h to 72 h in all 
samples apart from SE4, however, when both SEERYTH and SE parent strains were grown together SE 
was significantly fitter than SEERYTH strains. SE3-SE5 SEDOXY and SECIPRO SE5 samples had gradual biofilm 
growth and a downregulation of virulence genes, this mechanism is known to cause chronic infections 
(Johns et al., 2015). Some internalisation systems have been reported in S. epidermidis, such as SdrG 
and AtlE. This highlights S. epidermidis pathogenic process and the site where bacteria can survive to 
cause persistent infections (Bresco et al. 2017). Biofilm resistance is attributed to “persisters” which 
are cells capable of surviving the initial effect of an antibiotic, and if left unhindered, regeneration of 
the biofilm occurs. The possibility of persister cells playing a role in biofilm tolerance was firstly 
suggested by Kim Lewis (2001), this hypothesis was then reinforced by Levin and Rozen (2006), as they 
provided mathematical evidence of persister cells hampering bacterial infection treatment. 
Persistence is one of many examples of phenotypic heterogeneity, persister cells are able to survive 
stress conditions that genetically homogenous population would not survive. Persister cells are 
metabolically dormant, hence, concentrations of antibiotics cannot eliminate them (Lewis, 
2013).  Persister cells breakdown carbon sources and are observed to have a cellular respiration, they 
develop in a continuous stochastic manner, reaching a rate of 1% in biofilm or in stationary phase 
(Defraine et al., 2018). 
Bacterial cells and persistent strains in the stationary phase of biofilm growth utilise quorum-sensing 
to control the combined activities of the microbial populace, hence, stimulating greater resistance to 
antibiotics (Beuchat et al., 2011; Peng et al., 2019). Other influences that can possibly increase 
microbial resistance and cross-resistance to several physical and chemical stresses include stimulation 
of stress genes, introduction of antibiotics, synthesis of stress-related proteins such as chaperones 
(Beuchat et al., 2011; Peng et al., 2019). Furthermore, pathogenic genomic islands that exist on 
bacterial chromosomes modulate the production of chaperone proteins, quorum sensing signals or 
antibiotic exposure may augment the production of pathogenic traits, e.g. synthesis of toxins and 
invasive proteins (Beuchat et al., 2011; Peng et al., 2019). 
 
Some persistence strategies are similar to antibiotic resistance mechanisms utilised by bacteria, for 
example, efflux pumps play a major role in both anti-infective drug resistance and persistence 
mechanisms in mycobacteria (Adams et al., 2011) and E.coli (Pu et al., 2016). The persister cells are 
not antibiotic-resistant mutants, as they return to being a wild type after additional culturing (Defraine 
et al., 2018). 
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 The persister cells are usually elevated in immune compromised states due to the inability of the 
immune system to assist antibiotic eliminating the targeted biofilm cells (Figure 15) (Lewis, 2013). 
Moreover, persister cells can protect themselves from host defence system via biofilm matrix as well 
as blood-brain barrier in both biofilm and eukaryotic cells (Buyck et al., 2013). Antibiotics must merge 
with additional agents to have an increased impact against persisters (Defraine et al., 2018). Recently, 
persister cells have been eliminated by combining aminoglycosides and specific metabolites in an in 
vivo mouse model, the results showed that persistent cells are ‘primed for metabolite uptake and 
respiration’. Cells that remain within the biofilm may add to persistence, low-level infections, 
especially in S. epidermidis by not expressing Agr (Peng et al., 2019).  
 
4.3	Cross	resistance	
Microbes can adapt to anti-infective drugs by developing a reduced sensitivity, leading to cross-
resistance. Microbial cross-resistance is linked to single nucleotide polymorphism, alteration in 
membrane surface charge and phospholipid profile. Moreover, microbial cross-resistance is 
associated with modification in expression of enzymes, gene inducers/repressors and lateral transfer 
of resistant genes (Figure 16) (Candido et al., 2019).  
Figure 15. Schematic representation of biofilm resistance centred upon the survival 
of persisters. A preliminary application of high dosage confirms that the continuous 
supply of antibiotic eliminates planktonic bacteria alongside the bulk of biofilm 
bacteria. However, persisters stay active and revive biofilm, thereby instigating 
relapse of infection (Lewis, 2013). 
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Figure 16. Microbial cross resistance mechanisms to antibiotics and biocide (Candido et al., 2019). 
When bacteria are exposed to sub-lethal antibiotic concentrations the cell membrane dynamics 
are modified.  The lipopolysaccharide (LPS) is altered by AMPs, such as colistin, possibly leading to 
resistance to host AMPs e.g. cathelicidin antimicrobial peptide (LL-37). Antibiotics, biocides and 
AMPs usually regulate efflux pumps by removing anti-infective compounds from the bacteria. 
Both outer and inner membrane permeability is altered via reduced depolarisation and 
augmented negative membrane potential. Lastly, contact with biocides, such as triclosan, can 
stimulate assembly and secretion of extracellular polymeric substances to aid biofilm 
development (Candido et al., 2019). 
 
4.4	Virulence	strains	in	G.	mellonella		
S. epidermidis strains are generally incapable of causing aggressive infections in healthy hosts due to 
low virulence factors. The frequency of death in G. mellonella is observed in this study and is 
incidentally caused by microbial pathogenicity. In this research, there is an increase in number of G. 
mellonella larvae dying rapidly after being injected with the most virulent bacteria variant, such as, 
erythromycin and doxycycline adapted S. epidermidis variants. The antibiotic-adapted S. epidermidis 
strains (SEERYTH and SEDOXY) with higher biofilm formation capacity were able to resist G. 
mellonella immune defense mechanisms and cause infection, this can be related to certain virulence 
factors. The pathogenicity can be caused by the presence of various virulence substances including 
adhesin, fimbriae, bacterial capsule and proteins that assist attaining host nutrition, in due course this 
allows the microbe to survive and persist in the wax worm host (Chiers et al., 2010). Furthermore, 
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some S. epidermidis strains are known to produce PSM-mec with cytolytic capacity for neutrophils in 
vitro and PSM-mec has been linked to reduced microbial clearance as well as high mortality rates in S. 
epidermidis infected mice model (Qin et al., 2017). Similarly, this is observed in this study where SEERYTH 
and SEDOXY infected insects had much higher mortality rates than parent strain (SE) infected 
waxworms. An additional possibility is that the SEERYTH and SEDOXY strains evaded the G. mellonella 
immune system by having a cytotoxic effect on haemocytes, for example, disrupting the actin 
cytoskeleton, DNA synthesis inhibition and inducing apoptosis (Qin et al., 2017). On the other hand, 
SE strains with little to no pathogenicity may have quickly been eliminated via insect host defence 
response, however, other more virulent strains, hence, becoming persistent. The parent strains in 
general did not cause infections within the insects till day 4 possibly due to haemocytes in G. 
mellonella mediating cellular responses like encapsulation, phagocytosis and clotting (Satyavathi et 
al., 2014; Brown & Clarke, 2017), thus, successfully clearing sepsis in most wax worms. G. mellonella 
humoral response may have also cleared SE strains via soluble effector substances involving 
complement-like proteins, melanin, antimicrobial peptides and products produced by proteolytic 
cascades such as phenoloxidase pathway, which may restrict or kill SE strains (Eleftherianos & Revenis, 
2011). The findings from this study is substantiated by multiple relevant research journals that 
demonstrate how raised level of bacterial virulence is linked to the multiplication of bacteria in G. 
mellonella larvae and in contrast to this, low level of bacteria virulence is associated with microbial 
clearance (Evans & Rozen, 2012; Loh et al., 2013; Norville et al., 2014). 
As recommended by Maillard et al. (2013) and SCENIHR (2014) it is important to carry out further tests 
once a consistent alteration in antibiotic susceptibility is observed, this is done to comprehend and 
report the nature of bacterial alterations.  Molecular approaches can be utilised (e.g. microarray 
analysis or PCR) to study changes within the bacteria caused by constant antibiotic exposure (Yu et al., 
2012).  It is imperative for a researcher to study bacterial transcriptome and proteome as genotypic 
variations can possibly be resistance markers and provide information on antibiotic resistance 
mechanisms. 
4.5	MSE	analysis	
Throughout the extraction method for MSE analysis intracellular metabolites were exposed to the 
organic solvent methanol (-48 °C) For an optimal metabolome analysis, this solvent did not physically 
nor chemically alter or destroy the metabolites (Goodacre et al., 2005). Methanol has the capacity to 
extract as many metabolites possible, both hydrophilic and lipophilic molecules or substances. To 
quench the metabolic processes of cells, immediate temperature changes are applied at either high 
(> +80 °C) or low temperature (< -40 °C). Meyer, Liebeke and Lalk (2010) found that cold extraction 
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procedures were more efficient than a hot extraction (boiling water) for Gram-positive S. aureus 
bacteria. The is due to boiling extraction method degrading some of the metabolites (Meyer et al., 
2010). For Gram-positive S. epidermidis a mechanical cell disruption is required, this is because the 
cell wall will not break sufficiently using only an organic solution. For the cell wall disruption glass 
beads were effectvely used to break the cell wall and release metabolites. 
The main experiment for metabolomics failed to gain reliable results for profiling and analysis. 
However, the first quenching and metabolite extraction method was proven effective during a small 
trial run at Waters for mass spectrometry analysis. Few extracted metabolite samples (in triplicate) 
were transported to Waters, the mass spectrometry gave a positive response with high reliable target 
peaks. This validated the metabolite extraction method which was modified specifically for S. 
epidermidis from Goodacre et al. (2005) metabolomics guideline document. For the trial run at 
Waters, the MHB overnight culture media volumes were 1, 5, 10, 20 & 50 mL to test and optimise how 
much biomass is needed to get a positive response from MSE. However, for the main experiment due 
to the lack of time and Waters MSE test run deadline the colonies were directly taken from the 
overnight agar plates into the freezing organic solvent, instead of being grown in culture media at 
different volumes first, this may have affected the results (Kragh et al., 2018). The inoculation method 
for the main experiment was inconsistent compared to the trial run, this consequently substantially 
influenced the experiment result (Kragh et al., 2018).  
This research study found no conceivable information from the results received by Waters MSE 
analysis (Figure 14). The three typical stages used to process metabolomics data are to first pre-
process the raw data for comparison between different data sets. Secondly, to reduce the size of the 
data to its significant variables and lastly, to store data (Brown et al. 2012). Even if an identical 
analytical MSE instrument and extraction methods were used, there is no assurance that the entire 
metabolome has been profiled, the metabolomics community accepts that there is no instrument that 
can measure everything (Trivedi et al., 2017).   
Conventional methods used to measure quantifiable metabolome substances rely on calibration curve 
or the spike in stable isotope labeled internal standards (Schelli et al., 2017). Nevertheless, methods 
that rely on calibration curves are time – consuming and susceptible to inaccuracy. Furthermore, 
methods based on the spikes of stable isotope labeled internal standards are usually expensive and 
not easily accessible (Schelli et al., 2017). Thus, it is important for improved alternate methods for 
sensitive, accurate and quantitative metabolite analysis.  
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS) is capable of separating compounds 
within samples as it has the power of High Performance Liquid Chromatography (HPLC) and a detector 
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called Mass Spectrometry (MS) (Schelli et al., 2017). HPLC detectors can detect compounds that have 
one or more elements including ultra violet absorption, fluorescence or electrical conductivity (Schelli 
et al., 2017). Substance identification occurs indirectly. The components retention time is paralleled 
with a standard, if they are the same then it is almost certain that the component has been identified 
correctly. HPLC detectors have the ability to measure and quantify existing compounds, this is done 
by relying on the intensity and extent of the pure peaks during known retention times (Schelli et al., 
2017). Moreover, HPLC can provide excellent resolution, however the detectors are restricted in their 
capacity to detect accurately and measure compounds during specific conditions (Schelli et al., 2017). 
One example of this is when several compounds are inadequately divided on the column. This 
situation may arise when inspecting for novel antibiotic metabolites as the drug component properties 
are not identified or if the compound has two isomers. 
Characterisation of several extracellular and intracellular metabolites is generally done in vitro via 
numerous analytic devices such as HPLC-MS/MS (Schelli et al., 2017). HPLC-MS/MS machineries have 
allowed concurrent analysis of multiple metabolites from known biotic processes (Zhong et al., 2018). 
This approach may offer more precise quantification instead of the conventional universal approach 
used to characterise untargeted metabolites, enabling the detection of known metabolites for fast 
and simple study of biotic processes (Dunn et al., 2013). Both powerful analytical techniques HPLC and 
MS/MS can be combined and utilised. Moreover, the HPLC can split a sample into compounds of its 
component, the compounds are then tested in MS producing a spectra for every chemical entity. The 
structural information and molecular mass of the sample components can be determined by using the 
data HPLC MS/MS produces (Dunn et al., 2013). 
This facility is progressively used to record relative alterations in research fixated on cellular 
metabolite concentrations stimulated by environmental and genetic perturbations. However, relative 
concentration fluctuations can be helpful, information on absolute metabolite concentration is an 
important factor to understand the biochemical responses, enzyme kinetics and other significant 
biotic systems in living cells (Dunn et al., 2013). Consequently, there is a growing need of improved 
methods to focus on defining absolute metabolite concentrations extracellularly and intracellularly 
(Dunn et al., 2013).  
The combination of LC-MS and MS enables more powerful detection with increased sensitivity to 
detect metabolites accurately (Zhong et al., 2018). It is a challenge to differentiate constitutional 
isomers via HPLC and difficult to detect using MS (You et al., 2014; Schelli et al., 2017). MS detect ions 
generated by constitutional isomers, however, the isomers are mostly identical thus the variations in 
mass-to-charge ratio is usually not detected. There are many methods that can be used to overcome 
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this complication, one particular technique is LC-MS/MS. Ions produced for MS can be further 
disintegrated, hence, allowing LC-MS/MS to detect similarly arranged isomers (Lu et al., 2006). 
4.6	Conclusion 
In conclusion, antibiotic adapted S. epidermidis strains from human skin showed multi-resistance, 
including resistance to erythromycin, which is mainly associated with ermC gene.  
The results showed high levels of adaptive resistance toward erythromycin (100%). Erythromycin 
adapted strain had significantly enhanced fitness advantage (w value- 1.35, p value- 0.0427) and were 
significantly virulent (p-value of 0.047733) when compared to the parent strain. It can be concluded 
that antibiotic resistance continues to pose threat associated with public health in the hospital due to 
emerging bacterial resistance and multi-drug resistant bacteria. The increased rate of erythromycin, 
doxycycline and ciprofloxacin resistance among S. epidermidis isolates and the cross-resistance 
amongst the bacterial isolates in this study, emphasise the rapid necessity for adequate and 
appropriate execution of antibiotic stewardship programmes at all levels. Further investigation is 
needed to establish resistance determinants. Further in vivo studies are also needed to discern the 
impact that conditions on the skin, such as temperature, dryness, nutrients, horizontal gene transfer, 
and genetic factors, may have on pathogenicity and virulence. 
 
4.7	Recommendations	
Ø Examination of implant surface S. epidermidis biofilms should be monitored and evaluated, 
the dissemination of bacteria strains resistant to antibiotics should be observed at regular 
intervals from healthcare settings. 
Ø Strict measurement and precautions should be taken to control the spread of infections; this 
includes isolating infected patients. Also, the visitors and healthcare employees responsible 
for patient care should regularly wash their hands after each visit.  
Ø The prescribed antibiotic for patients in healthcare places such as hospitals should be 
reviewed after every few days, and altered according to the antibiotic sensitivity report, or 
should fully stop using the given antibiotic if the suspected pathogens are not found in the 
culture tests.  
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APPENDICES 
Two W-values for each group of samples are calculated. For p-value, five p0 end samples and p9 end 
samples were compared for both axenic and binary.  
Mean axenic: In (p9 end/p9 start)/In(p0end/p0start)   
Mean binary: In (p9 end/p9 start)/In(p0end/p0start) 
Table 13. Competitive fitness data of parent and adapted bacterial strains (x 10⁻⁵) 
SEERYTH  Axenic  
p0 start  
Axenic 
p0 end  
Axenic p9 
start  
Axenic  
p9 end 
Binary p0 
start 
Binary p0 
end 
Binary p9 
start 
binary 
 p9 end 
SE1 4.49  5.55  4.59  5.68 4.09 7.89 3.40 4.57 
SE2 4.48  5.56  4.14  5.41 3.98 6.08 2.56 5.07 
SE3 3.97  5.68  4.21  5.44 4.19 6.77 2.98 5.57 
SE4 4.37  5.68  3.79  5.36 3.88 5.06 2.14 4.39 
SE5 4.19  5.47  4.29 5.55 3.90 5.10 2.20 4.21 
mean 4.30  5.59  4.21 5.49 4.01 6.18 2.65 4.76 
p-value 
   
0.2     
 
0.043 
Standard 
deviation 
   
0.11 
   
0.93 
W-value 
   
1.02 
   
1.35 
SEDOX Axenic  
p0 start 
Axenic 
p0 end 
Axenic p9 
start 
Axenic  
p9 end 
Binary p0 
start 
Binary p0 
end 
Binary p9 
start 
Binary  
p9 end 
SE1 5.59 6.99 3.40 4.77 4.82 7.59 3.21 2.54 
SE2 5.88 6.78 3.26 4.97 4.94 7.69 2.25 3.45 
SE3 4.89 6.27 3.98 4.87 4.96 7.62 2.72 3.26 
SE4 5.47 7.06 3.94 4.69 4.85 7.65 2.34 3.65 
SE5 5.00 6.10 3.60 4.51 4.99 7.62 2.83 2.88 
mean 5.36 6.64 3.63 4.76 4.91 7.63 2.67 3.16 
p-value 
 
  
 
0.0001 
 
  
 
0.0001 
Standard 
deviation 
 
  
 
0.33 
 
  
 
0.31 
W-value 
 
  
 
1.27 
 
  
 
0.38 
SECIPRO  Axenic  
p0 start 
Axenic 
p0 end 
Axenic p9 
start 
Axenic  
p9 end 
Binary p0 
start 
Binary p0 
end 
Binary p9 
start 
Binary 
p9 end 
SE1 6.69 6.73 3.32 3.57 5.89 8.09 3.57 2.99 
SE2 6.50 6.69 3.26 3.46 5.98 7.98 3.13 4.57 
SE3 6.49 7.89 3.06 3.71 5.59 7.77 3.32 3.46 
SE4 6.57 6.57 3.32 3.34 5.33 8.16 2.55 2.95 
SE5 6.49 7.34 3.10 3.71 5.43 7.60 2.40 3.46 
mean 6.54 7.05 3.21 3.56 5.64 7.92 2.99 3.49 
p-value 
 
  
 
0.0001 
 
  
 
0.0002 
Standard 
deviation 
 
  
 
0.16 
 
  
 
0.65 
W-value 
 
  
 
1.39 
 
  
 
0.45 
 
